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1. INTRODUCTION
1.1 DRUG DELIVERY SYSTEM 
The treatment of acute diseases or chronic illness has been achieved by delivery of drugs
to  the  patients  for  many  years.  These  drug  delivery  systems  include  tablets,  injectables,
suspensions,  creams, ointments, liquids and aerosols.  Today these conventional drug delivery
systems are widely used. The term drug delivery can be defined as techniques that are used to
get the therapeutic agents inside the human body. Another role of the delivery systems is to allow
the  safe  application  of  the  drug.  This  includes  that  the  drug  in  the  formulation  must  be
chemically,  physically  and  microbiologically  stable.  Side-effects  of  the  drug  and  drug
interactions should be avoided or minimised by the use of suitable drug delivery systems. The
delivery systems also need to improve the patient’s compliance with the pharmacotherapy by the
development of convenient applications. For example, one can improve patient compliance by
developing  an  oral  dosage  form where  previously only  parenteral  application  was  possible.
Finally,  the delivery system needs to be reliable and its  formulation needs to be technically
feasible. This means the Pharmaceutical quality of the delivery systems needs to be assured, drug
release from the system needs to be reproducible and the influence of the body on drug release
should be minimized. (For example, food effects after oral administration.) 1, 2
Drug delivery systems
1. Conventional drug delivery systems
2. Controlled drug delivery systems
1.2 Conventional Drug Delivery Systems 
Conventional drug therapy requires periodic doses of therapeutic agents. These agents are
formulated  to  produce  maximum  stability,  activity  and  bioavailability.  For  most  drugs,
conventional  drug  delivery  is  effective,  but  some  drugs  which  possess  narrow  therapeutic
window and which cause irritation to gastric mucosa requires modified drug delivery system to
achieve desired therapeutic effect. These delivery systems have a number of advantages over
traditional  systems  such  as  improved  efficiency,  reduced  toxicity  and  improved  patient
convenience. The main goal of modified drug delivery systems is to improve the effectiveness of
drug therapies.
Conventional dosage forms are rapidly absorbed, with the ascending and descending portions
of  the  concentrations  versus  time  curve  reflecting  primarily  the  rate  of  absorption  and
elimination,  respectively.  Because  of  the  rapid  rate  of  absorption  from conventional  dosage
forms, drugs are usually administered more than once daily, with the frequency being dependent
on biological half- life (t½) and duration of pharmacological effect. The time of dosing may also
be effected by therapeutic index of a drug. 3, 4, 5
1.2.1 Disadvantages of Conventional Drug Delivery Systems 
• In conventional oral drug delivery systems, there is little or no control over the release of
the drug and effective concentration at the target site.
• The  dosing  pattern  in  conventional  dosage  forms  results  in  constantly  changing,
unpredictable and often sub-therapeutic plasma concentrations, leading to marked side
effects in some cases.
• Conventional drug delivery system is not suitable for the drugs which cause irritation to
the gastric mucosa.
• The  rate  and  extent  of  absorption  of  drug from conventional  formulations  may vary
greatly,  depending  on  the  factors  such  as  physicochemical  properties  of  the  drug,
presence of excipients, various physiological factors such as the presence or absence of
food, pH of the gastrointestinal tract, gastrointestinal motility and so on.6
1.3 MODIFIED DRUG DELIVERY SYSTEMS 
Dosage forms can be designed to modify the release of the drug over a given time or after the
dosage  form  reaches  the  required  location.  Drug  release  only  occurs  sometime  after  the
administration  or  for  a  prolonged  period  of  time or  to  a  specific  targeted  site  in  the  body.
Modifications in drug release are often desirable to increase the stability, safety and efficacy of
the drug, to improve the therapeutic outcome of the drug treatment and/or to increase patient
compliance and convenience of administration. 7
 Classification:
Modified Release dosage form may be classified as
 Extended Release
• Sustained Release
• Controlled Release
 Delayed Release
1.3.1. Extended Release: 
This type of oral DDS allows the drug to be released over prolonged time periods. By extending
the release profile of a drug, the frequency of dosing can be reduced.  Extended release can be
achieved using sustained or controlled-release dosage forms.
1.3.2. Sustained Release: 
This term is constantly used to describe a pharmaceutical dosage form formulated to retard the
release of the therapeutic agent such that its appearance in the systemic circulation is delayed and
prolonged and its plasma profile is sustained in duration. The onset of its pharmacological action
is often delayed, and the duration of its therapeutic effect is sustained.
 In  orally administered dosage forms, this duration is in hours and critically depends on the
residence time of the dosage form in GI tract, whereas in the case of injectable this period may
vary from days to months.
1.3.2a. Advantages of SR Dosage Forms: 
 Improved patient compliance due to reduced frequency of drug administration.
 The blood level oscillations characteristic of conventional dosage forms is reduced.
 A less obvious advantage that the total amount of drug administered can be reduced, thus
maximizing availability with minimum dose.
 Better control of drug absorption can be attained, since the high blood level peaks that
may be observed after administration of a dose of high availability drug can be reduced
by formulation in an extended action form.
 The safety margin of high potency drugs can be increased, and the incidence of both local
and systemic adverse side effects can be reduced in sensitive patients.
 Reliable therapy. [9]
1.3.2b. Disadvantages: 
• Administration of SR medication does not permit the prompt termination of therapy.
• Less flexibility in adjusting dosage regimen.
• Sustained  release  forms  are  designed  for  normal  population,  i.e.,  on  the  basis  of
biological half-lives. Consequently, disease states that alter drug disposition, significant
patient variation, and so forth are not accommodated.
• Economic factors. [9]  
1.3.2c. Drug candidates those are suitable for SR Dosage Forms:
 Should be effectively absorbed in small intestine.
 Biological half- life should lie within 1-12hours.
 Dosage that is not titrated according to individual.
 Small doses(<1g) [9] 
 
      Fig.1  Plasma Dug Concentration Profiles  for Conventional  Tablet  Formulation,  a
Sustained Release Formulation and a Zero Order Controlled Release Formulation.       
SR system generally don’t attain zero order type release and usually try to mimic zero order
release by providing drug in a slow first order. Repeat action tablet are an alternative method of
sustained release in which multiple doses of drug are contained within a dosage form and each
dose is released at a periodic interval. Delayed release system, in contrast, may not be sustaining,
since often the function of these dosage forms is to maintain the drug in the dosage for some time
before its release, Eg: Enteric coated tablet. 
The ideal way of providing an exact amount of drug at the site of action for a precise time period
is usually approximated by most systems. This approximation is achieved by creating a constant
concentration in the body organ over an extended time;  in other  words,  the amount of  drug
entering the system is equivalent to the amount of drug removed from the system. All forms of
metabolism and excretion are included in the removal process: urinary excretion, enterohepatic
recycling, sweat, fecal and so on. Since, for most of the drugs these elimination processes are
firstorder,  it  can  be  said  that  a  certain  blood  level,  the  drug  will  have  a  specific  rate  of
elimination.  The  idea  is  to  deliver  drug  at  this  exact  rate  for  an  extended  period.  This  is
represented mathematically as following,
                             Rate in = Rate out = kelim × Cd × Vd
Where Cd is the desired drug level, 
           Vd is the volume of distribution, and
          kelim is the rate constant of drug elimination from the body.
1.3.3. PHYSICOCHEMICAL FACTORS INFLUENCING ORAL SUSTAINED-RELEASE
DOSAGE FORM DESIGN [13, 14]
a. Dose size
For  orally  administered  systems,  there  is  an  upper  limit  to  the  bulk  size  of  the  dose  to  be
administered. In general, a single dose of 0.5- 1.0g is considered maximal for a conventional
dosage form. This also holds for sustained release dosage form. Compounds that require large
dosing size can sometimes be  given in  multiple  amounts  or  formulated  into  liquid systems.
Another consideration is the margin of safety involved in administration of large amount of a
drug with a narrow therapeutic range.
b. Ionization, pka and aqueous solubility 
Most drugs are weak acids or bases. Since the unchanged form of a drug preferentially permeates
across lipid membranes, it is important to note the relationship between the pka of the compound
and the absorptive environment. Presenting the drug in an unchanged form is advantageous for
drug permeation. Unfortunately, the situation is made more complex by the fact that the drug’s
aqueous  solubility  will  generally  be  decreased  by  conversion  to  unchanged  form.  Delivery
systems  that  are  dependent  on  diffusion  or  dissolution  will  likewise  be  dependent  on  the
solubility of the drug in aqueous media. These dosage forms must function in an environment of
changing pH, the stomach being acidic and the small intestine more neutral, the effect of pH on
the release process must be defined.
Compounds with very low solubility (<0.01mg/ml) are inherently sustained, since their release
over the time course of a dosage form in the GI tract will be limited by dissolution of the drug.
So it is obvious that the solubility of the compound will be poor choices for slightly soluble
drugs, since the driving force for diffusion, which is the drug’s concentration in solution, will be
low.
c. Partition Coefficient 
When a drug is administered to the GI tract, it must cross a variety of biological
Membranes to produce a therapeutic effect in another area of the body. It is common to consider
that these membranes are lipidic; therefore the partition coefficient of oil-soluble drugs becomes
important in determining the effectiveness of membrane barrier penetration. Compounds which
are lipophilic in nature having high partition coefficient are poorly aqueous soluble and it retain
in  the  lipophilic  tissue  for  the  longer  time.  In  case  of  compounds  with  very low  partition
coefficient,  it  is  very  difficult  for  them  to  penetrate  the  membrane,  resulting  in  poor
bioavailability.  Furthermore,  partitioning  effects  apply  equally  to  diffusion  through  polymer
membranes. The choice of diffusion-limiting membranes must largely depend on the partitioning
characteristics of the drug.
d. Stability
Orally  administered  drugs  can  be  subjected  to  both  acid-base  hydrolysis  and  enzymatic
degradation. Degradation will proceed at a reduced rate for drugs in solid state. For the dosage
form that are unstable in stomach, systems that prolong delivery over entire course of transit in
the GI tract are beneficial; this is also true for systems that delay release until the dosage form
reaches the small intestine.  Compounds that  are unstable in small  intestine may demonstrate
decreased  bioavailability when  administered from a sustaining dosage  form.  This is  because
more drugs are delivered in the small intestine and, hence, is subject to degradation. 
1.3.4.  BIOLOGICAL  FACTORS  INFLUENCING  ORAL  SUSTAINED-RELEASE
DOSAGE FORM DESIGN [13,14]
· Biological half- life.
· Absorption.
· Metabolism.
a. Biological half life
The usual goal of an oral SR product is to maintain therapeutic blood levels over an
extended period of time. To achieve this, drug must enter the circulation at approximately the
same rate at which it is eliminated. The elimination rate is quantitatively described by the half-
life  (t1/2).  Each  drug  has  its  own  characteristic  elimination  rate,  which  is  the  sum  of  all
elimination  processes,  including  metabolism,  urinary  excretion  and  all  over  processes  that
permanently remove drug from the blood stream. Therapeutic compounds with short half-life are
generally are excellent candidate for SR formulation, as this can reduce dosing frequency. In
general, drugs with half-life’s shorter than 2 hours such as furosemide or levodopa are poor
candidates  for  SR preparation.  Compounds with long half-lives,  more than 8 hours  are  also
generally  not  used  in  sustaining  form,  since  their  effect  is  already  sustained.  Digoxin  and
phenytoin are the examples.
b. Absorption
Since the purpose of  forming a SR product  is  to place control  on the delivery system, it  is
necessary that the rate of release is much slower than the rate of absorption. If we assume that
the transit time of most drugs in the absorptive areas of the GI tract is about 8-12 hours, the
maximum half-life for absorption should be approximately 3-4 hours; otherwise, the device will
pass out of the potential absorptive regions before drug release is complete. This corresponds to a
minimum apparent  absorption  rate  constant  of  0.17-0.23h-1  to  give  80-95%  over  this  time
period. Hence, it assumes that the absorption of the drug should occur at a relatively uniform rate
over  the entire  length of small  intestine.  For  many compounds this  is  not  true.  If  a  drug is
absorbed  by  active  transport  or  transport  is  limited  to  a  specific  region  of  intestine,  SR
preparation  may  be  disadvantageous  to  absorption.  One  method  to  provide  sustaining
mechanisms of delivery for compounds is to maintain them within the stomach. This allows slow
release of the drug, which then travels to the absorptive site. These methods have been developed
as a consequence of the observation that co-administration results in sustaining effect. One such
attempt is to formulate low density pellet or capsule. Another approach is that of bio adhesive
materials.
c. Metabolism
Drugs those are significantly metabolized before absorption, either in the lumen or the tissue of
the  intestine,  can  show decreased  bioavailability  from slower-releasing  dosage  form.  Hence
criteria for the drug to be used for formulating Sustained-Release dosage form is,
· Drug should have low half-life(<5 hrs)
· Drug should be freely soluble in water.
· Drug should have larger therapeutic window.
· Drug should be absorbed throughout the GIT.
Even a drug that is poorly water soluble can be formulated in SR dosage form. For the same, the
solubility of the drug should be increased by the suitable system and later on that is formulated in
the SR dosage form. But during this the crystallization of the drug, that is taking place as the
drug is entering in the systemic circulation, should be prevented.
1.3.5. Controlled Release Dosage: 
CR dosage form is generally accomplished by attempting to obtain “zero- order” release from the
dosage form which is independent of the amount of drug in the delivery system (i.e., a constant
release rate). Sustained Release systems generally do not attain this type of release and usually
try to mimic zero order release by providing drug in a slow first order fashion (i.e., concentration
dependent).
The controlled release systems for oral use are mostly solids and based on dissolution, diffusion
or a combination of both mechanisms in the control of release rate of drug.
Depending upon the manner of drug release, these systems are classified as follows:
a. Continuous release systems 
These  systems  release  the  drug  for  a  prolonged  period  of  time  along  the  entire  length  of
gastrointestinal tract with normal transit of the dosage form.
The various systems under this category are as follows:
A. Dissolution controlled release systems
B. Diffusion controlled release systems
C. Dissolution and diffusion controlled release systems
D. Ion exchange resin- drug complexes
E. pH dependent formulation
F. Osmotic pressure controlled systems [13]
b. Delayed transit and continuous release systems
These systems are designed to prolong their residence in the GI tract along with their release.
Often the dosage form is fabricated to retain in the stomach and hence the drug present therein
should be stable in gastric pH. Systems included in this category are mucoadhesive systems and
size based systems. [13]
1.3.6. Delayed Release 
A Delayed Release dosage form is designed to release the drug at a time other than promptly
after administration. Dosage forms can be designed to modify the release of the drug over a
given time or after the dosage form reaches the required location.
Delayed Release oral dosage forms can control where the drug is to be released, e.g. when the
dosage  form  reaches  the  small  intestine  (enteric-coated  dosage  forms)  or  the  colon  (colon-
specific dosage forms). 
Delayed  Release  systems  release  a  bolus  of  the  drug  after  a  predetermined  time  in  a
predetermined location, i.e. they do not release the drug immediately after ingestion, for example
enteric-coated tablets, pulsatile-release capsules. 
Delayed Release dosage forms are designed to provide spatial placement or temporal targeted
delivery of a drug to the distal human gut. Spatial placement relates to targeting a drug to a
specific organ or tissue, while temporal delivery refers to desired rate of drug release to target
tissue over a specified period of time.
 The correct selection and balance of excipients and processes in solid dosage formulations are
designed either for improving the micromeritic or macromeritic properties of materials during
manufacture and/or  for  providing a desired drug delivery system.  The most commonly used
pharmaceutical  sustained  release  solid  oral  dosage  forms  today  include  tablets,  capsules,
granules and pellets. [14, 15]
1.4 MULTIPARTICULATES / MULTI UNIT DOSAGE FORMS
Multiple  unit  dosage  forms  are  essential  where  drug-excipients  or  drug-drug
physicochemical interaction is possible in a single-unit formulation, they are also known to have
less variance in transit time through the gastro intestinal tract than single unit dosage forms. They
are usually delivered in hard gelatin capsules or made into tablets that disintegrate instantly.
Types of Multiple unit dosage forms comprise
• Pellets
• Granules
• Mini tablets mini depots
• Micro particles (Microspheres or Microcapsules) and Nano particles
Multi particulates are
• Filled into hard-gelatin capsules
• Compressed tablets
• Suspended in liquids or
• Packed in sachets.
1.4.1 Features of the Performance of Multiparticulates 
Multi particulate dosage forms have a number of useful features which can be used for
the advantage in modified release forms. Foremost is their ability to overcome the variation in
performance which may arise through variation in gastrointestinal transit time and, in particular,
variation occasioned by erratic gastric emptying. The size of most  multi particulates enables
them to pass through the constricted pyrolic sphincter so they are able to distribute themselves
along the entire gastrointestinal tract. As the dose of drug is spread out over a large number of
particles,  then  the  consequences  of  failure  of  a  few  units  has  nothing  like  the  potential
consequences  of  failure  through dose dumping of  a  single  coated  tablet  used as  a  modified
release  dosage  form.  Additionally,  as  the  drug  is  not  all  concentrated  in  one  single  unit,
considerations of an irritant effect  to the mucosal  lining of the gastrointestinal tract are very
much reduced. 16
1.5 PELLETS11,19
           Pellets are agglomerates of fine powders or granules of bulk drugs and excipients. They
consist of small, free flowing spherical or semi spherical solid units typically from about 0.5-
1.5mm. These are intended usually for oral administration. 
1.5.1 Desirable Properties of Pellets:
              Pellets may be uncoated type or coated type.
a) Uncoated pellets:  
Uncoated pellets must have following properties
•  Uniform spherical shape and smooth surface.
•  Optimum size of pellets is between 600 and 1000?m.
•  Good flow properties.
•  High physical strength and integrity.
•  Good hardness and low friability.
•   High bulk density.
•   Ease and superior properties for coating.
•   Reproducible packing of beds and columns.
b) Coated pellets: Along with the above properties, the coated pellets must contain as much as
possible  of the active ingredient to keep the size of the final dosage form  within reasonable
limits.
                      
                  (a) Pellets, (b) Perfect pellet, (c) Coated pellet
                              Figure 2: Different types of pellets
1.5.2 Stages in Pellet Formation and Growth:
Formation and growth of pellets can be divided into four stages:
1. Pendular state
2. Funicular state
3. Capillary state
4. Droplet state.
           
 Figure 3: Different formal spatial structures of liquid-bound agglomerates 
1.5.3 Advantages of pellets:  
• Improved appearance of the product which is having fine pharmaceutically elegant.
• Pelletization offers flexibility in dosage form design and development.
• Pellets improve the flow properties in formulation development.
• Pellets are less susceptible to dose dumping.
• It reduces localized concentration of irritative drugs.
• It improves safety and efficacy of a drug.
• Pellets offer reduced variation in gastric emptying rate and transit time.
• Pellets disperse freely in G.I.T. and invariably maximize drug absorption and also reduce
peak plasma fluctuation.
• Pellets ensure improved flow properties in formulation development.
• Pelletization is a convenient way to manage the separation of incompatible drugs.
• Chemically incompatible products can be formed into pellets & delivered in a single
dose by encapsulating them.
• The most important reason for the wide acceptance of multiple unit products is the rapid
increase in popularity of oral pellets dosage forms, Pellets oral solid dosage forms are
usually  intended  either  for  delivery  of  the  drug  at  a  specific  site  within  the
gastrointestinal tract or to sustain the action of drugs over an extended period of time.11
1.5.4 Disadvantages of pellets:
• The manufacturing of multiple unit dosage forms is more complicated and more 
expensive.
• The filling into gelatin capsules is difficult to accomplish, especially in the case where 
different subunits are involved.
• Scale-up of pellets is a very complicated one. 
1.5.5 Theory of pellet formation and growth 
Before selection and optimization of any pelletization/granulation process, it is important
to understand the fundamental mechanisms of pellet formation and growth. Different theories
have been postulated related to the mechanism of formation and growth of pellets. Some of these
theories are derived from experimental results while others are derived by visual observations.
Out of these hypothetical theories the most convincing classification of Pelletization process,
involves three consecutive regions: nucleation, transition and ball growth. However, based on the
experiments  on  the  mechanism  of  pellet  formation  and  growth,  the  following  steps  were
proposed: nucleation, coalescence, layering and abrasion transfer.
Nucleation is a stage of pelletization process that occurs whenever a powder is wetted
with solvent system. The primitive particles are drawn together to form three-phase air-water-
liquid nuclei system which are held together by liquid bridges that are pendular in nature. The
reduction of particle size will improve the bonding strength between them. Further the size, the
rate and the extent of nuclear formation depends upon the size of the particles,  the moisture
content, the viscosity of the binding particles, the wet ability of the substrate and the processing
conditions, such as tumbling and drying rates.
Nucleation is followed by a transition phase where the growth mechanisms affecting are
coalescence and layering.  Coalescence is  defined as the formation of large-sized particles by
random collision of well-formed nuclei, this mechanism require slightly excess moisture on the
surface of the nuclei although the number of nuclei is progressively reduced even though the
total mass of the system remains unchanged during this operation. Layering is a slow growth
mechanism and with the successive addition of fragments and fines on an already formed nuclei.
In the layering step, the number of particles remains constant while the total mass of the system
increases due to increasing particle size as a function of time. The fragments or fine particles can
be formed by particle size reduction.
The fines  and  the  fragments  produced  through size  reduction are  taken up by larger
pellets. Production of fines and subsequent coalescence and layering continues until the number
of collisions declines rapidly, thereby leading to a reduction in the rate of growth of the pellets.
At this point the third phase, the ball growth region, is reached. The main mechanism in the ball
growth phase is the abrasion transfer which involves the transfer of materials from one granule
formed to another without any preference in either direction. This phase does not result in any
change in the total number or mass of the particles. However, the particles undergo a continuous
change in their size as long as the conditions that lead to the transfer of material exist. 11, 12
1.5.6 Pelletization techniques 11,19
Pelletization is an agglomeration process that converts fine powders or granules of bulk
drugs and excipients into small, free-flowing, spherical or semi-spherical units, referred to as
pellets.
The most commonly used and intensely investigated pelletization processes are 12
1. Powder layering, 
2. Solution/Suspension layering, and 
3.Extrusion–Spheronization.
Compaction and drug layering are the most widely used pelletization techniques in 
Pharmaceutical industry. Other pelletization methods such a globulation, balling and 
compression are also used in development of pharmaceutical pellets although in   a limited scale
               Fig.No 4: Different pelletization techniques 
1.5.6.1 LAYERING
a) Powder layering:           
Powder layering involves the deposition of successive layers of dry powders of drugs and
excipients of formulation on spheres of inert material of sugar with the help of a binding liquid
during powder layering a binding solution and a finely milled powder are added simultaneously
to a bed of starter spheres at a controlled rate.  In the initial stages the drug particles are bound to
the  starter  spheres  and  subsequently  to  the  forming  pellets  with  the  help  of  liquid  bridges
originated from the sprayed binding liquid.  Successive layering of the drug and binding solution
continues until the desired pellet size is achieved. 10, 12
Fig.No.5: Depicts the principle of powder layering
b) Solution / Suspension layering: 
                    Solution/suspension layering involves the deposition of successive layers of 
solutions or suspensions of drug substances and binders over the starter/non-pareil seeds, which 
is an inert material or crystals/granules of the same drug. During solution or suspension layering 
all the components of the formulation are dissolved or dispersed in the application medium.  As 
the solution or suspension is sprayed on to the spheres (staring core) the droplets impinge on the 
starter spheres and spread evenly on the surface provided favorable drying and fluid conditions.  
This is followed by a drying phase which allows dissolved material to crystallize and form solid 
bridges between the core and initial layer of the drug substance as well as among the successive 
layers of the drug substances.  The process continues until the desired pellet size is achieved. 
In fact the coating process involved in general is applicable to solution or suspension
layering  technology.  Consequently  conventional  coating  pans,  fluidized  beds,  centrifugal
granulators, Wurster coaters have been used successively used to manufacture pellets by this
method. The efficiency of the process and the quality of the pellets produced are in part related to
the type of equipment used. 10, 12
Fig.No.6: Depicts the principle of solution and suspension layering, 
c)  Direct pelletization: 
Direct  pelletization  process  leads  to  formation  of  homogeneous  pellets  which  have
microscopically uniform structure and no core can be detected. The pelletization of powdered
starting materials  is  facilitated  by the addition of  binder  liquid and a  suitable  movement  of
wetted  powders.  The  impact  and  acceleration  forces  that  occur  in  this  process  result  in  the
formation of agglomerates, which become rounded out into uniform and dense pellets. The speed
of rotation has a direct influence on the density and size of the pellets. The solidification of the
pellets is achieved by drying the liquid. Direct pelletization processes are mainly performed in
high shear mixers and fluidized bed equipment. 11
Fig No.7: Depicts the principle of direct pelletization,
1.5.6.2 COMPREESION
a) Pelletization by Extrusion and spheronization:
Extrusion–Spheronization is a multistep process involving dry mixing, wet granulation,
extrusion, spheronization, drying, and screening. The first step is dry mixing of the drug and
excipients in suitable mixers followed by wet granulation, in which the powder is converted into
a  plastic  mass  that  can  be  easily  extruded.  The  extruded  strands  are  transferred  into  a
spheronizer, where they are instantaneously broken into short cylindrical rods on contact with the
rotating friction  plate  and  are  pushed  outward  and  up  the  stationary wall  of  the  processing
chamber by centrifugal  force.  Finally,  owing to gravity,  the particles fall  back to the friction
plate, and the cycle is repeated until the desired sphericity is achieved. 15, 16
Fig No.8: Depicts the principle of Extrusion & Spheronization, 
b) Compression:
It  is one type of compaction technique for preparing pellets. Compacting mixtures or
blends of active ingredients and excipients under pressure prepare pellets of definite sizes and
shapes.  The formulation and process  variables  controlling the quality of pellets  prepared are
similar to those used in tablets manufacturing.
1.5.6.3 AGITATION
a)Balling:
               It is the pelletization process in which pellets are formed by a continuous rolling and
tumbling motion in pans, discs, drums or mixtures. The process consists of conversion of finely
divided particles in to spherical particles upon the addition of appropriate amounts of liquid. The
liquid may be added prior or during the agitation stage.  As powder come in contact with a liquid
phase, they form agglomerates or nuclei which are initially bound together by liquid bridges that
are  subsequently  replaced  by solid  bridges  derived  from the  hardening  binder  or  any other
dissolved material within the liquid phase.
1.5.6.4 GLOBULATION or droplet formation consists two related processes, spray drying and 
spray congealing, involve atomization. Atomization of hot melts solution or suspensions to 
generate spherical particles pellets.
a) Spray drying:
During spray drying, drug entities in solution or suspension are sprayed, into a hot air
stream to generate dry and highly spherical particles.  As the atomized droplets come on contact
with hot air, evaporation of the application medium initiated.  The drying process continues until
the entire application medium is driven off and solid particles are formed.  Generally, spray dried
pellets tend to be porous. This process is commonly used for improving the dissolution rates;
hence bioavailability of poorly soluble drugs.
b) Spray congealing: 
It is the process in which a drug is allowed to melt, disperse or dissolve in hot melts of
gums, waxes or fatty acids, and is sprayed into an air chamber where the temperature is kept
below  the  melting  point  of  the  formulation  components,  to  provide  appropriate  processing
conditions  for  spherical  congealing of  pellets.   A critical  requirement  in  a  spray congealing
process is that the formulation components have sharp melting points or narrow melting zones.
Pellets produced by this process are dense and nonporous. Both immediate and controlled release
pellets  can  be  prepared  in  this  process  depending  on  the  physiochemical  properties  of  the
ingredients and other formulation variables.
1.5.6.5 OTHER PELLETIZATION METHODS 19
a) Cryopelletization:
In  cryopelletization,  droplets  of  liquid formulation are recovered in to solid  spherical
particles or pellets by employing liquid nitrogen as the fixing medium.  This technology can
produce drug-loaded pellets by allowing droplets of solution or suspension to come in contact
with liquid nitrogen at -1600C. The procedure permits instant and even freezing of the material
being processed due to the repaid heat transfer which occurs between the droplets and the liquid
nitrogen.  The pellets are dried in conventional freeze dryers. 
The most critical step in Cryopelletization is droplet formation, which is influenced not
only by formulation variables such as viscosity, surface tension and solid contents, but also by
equipment design and the corresponding processing variables.  The diameter and design of the
shearing edges of the holes on the container plates are also critical.  For instance, the diameter of
the holes determines the flow rate, which in turn is governed by the viscosity of the formulation.
The diameter of holes also influences the size and shape of the pellets.  The smaller the nozzle
diameter, the smaller the pellets produced.  The shape of droplets depends on the distance of the
droplets travel before contacting the liquid nitrogen. 11, 19
1.6 PELLET COATING PROCESS
The coating process for pellets is carried out primarily in order to modify the release of
the  drug from the  pelletized  drug delivery systems.  Following are  the  some of  the Coating
equipments used for this purpose
1. Conventional Coating Pan
2. Perforated Coating Pan
3. Fluidized Bed Processor
1.6.1 Conventional Coating Pan:
            The standard coating pan system consists of a circular metal pan mounted somewhat
angularly on a stand, the pan is rotated on its horizontal axis by a motor, the hot air is directed
into the pan and onto the bed surface, and is exhausted by means of ducts positioned through the
front of the pan. Coating solutions are applied by spraying the material on the bed surface. In this
technique the granules or sugar spheres are placed in the coating pan and the coating solution is
sprayed on the granules by atomizer with pressure.
 
Fig No.9: Conventional Coating Pan
1.6.2 The perforated Coating Pan:
 Perforated pan coaters are efficient drying systems with high coating capacity, and can
be  completely automated  for  both sugar  coating and  film coating processes.  There  are  four
different type of coaters available Acela-Cota, Hi-Coater, Driacoater, Glatt coater. In all four of
these perforated pan systems the coating solution is applied to the surface of the rotating bed of
pellets through spraying nozzles that are positioned inside the drum.10
1.6.3 Fluidized Bed Processor:
• One machine can perform multiple functions like coating, drying, granulation and pelleting.
• Highly efficient drying system.
•  Aqueous or organic coatings can be applied.
• Uniform continuous product coating achieved.
Applications:
1. Ideal  for  a  wide  range  of  process  applications  include  coating  hearing  drying
agglomeration and granulation.
2. Ideal for control release film coating, pellet granulation and hot melt coating.
3. Suitable for coating of micro particles, granules, pellets or tablets.
4. Specific manipulation of the particle surface characteristics.  Protection of the product
against moisture, light, air.
 Principle of operation:
With fluid bed coating particles are fluidized and the coating fluid sprayed on and dried.
Small droplets and a low viscosity of the spray medium ensure an even product coating.
Different types of fluidized bed processors are
A) Top spray coating
B) Bottom spray coating (Wurster coating)
C) Tangential spray coating (Rotor pellet coating)
1.6.3.1 Top spray coating:
This  process  is  used  to  spray  binder  solution  for  powder  granulation.   Particles  are
fluidized in the flow of heated air, which is introduced into the product container via a base plate.
The binder solution is sprayed into the fluid bed from above against the air flow (counter current)
by using nozzle.  Air volume is adjusted to have the center of the particle stream very close to the
nozzle.  Drying takes place as the particles to move upwards in the air flow.
                          
      TOP SPRAY                    BOTTOM SPRAY            TANGENTIAL SPRAY                        
Fig No.10: Depicts the types of fluid bed processor
Applications:
• Preferred when a taste masking coating is applied. Additionally suitable for the
application of hot melt coating.
• Continuous  spray  coater  is  particularly  suitable  for  protective  coatings/colour
coating.
1.6.3.2 Bottom Spray coating (Wurster coating):
The process is suitable for pellet suspension coating or film/sugar coating, particularly 
useful for a control release active ingredients.
           In this process, a complete sealing of the surface can be achieved with a low usage of
coating substance.  When the hot air flows through the bottom screen of container and coating
column, it will generate the siphonage principle.  Convection is created through the strong force
from bottom toward top.  The granules will then fall down and will be sucked into the coating
column again, while the bottom spray gun will spray towards top to achieve coating purpose.  As
the particles continue travelling upwards, they dry and fall outside the Wurster tube back towards
the base plate.
Table No.1: Parameters Used in Bottom Spray Equipment
Inlet temperature 38-42ºC
Product temperature 32-36ºC
Exhaust temperature 32-38ºC
Spray rate 8-12mg/min
Peristaltic pump 12-18 rpm
                      Fig No.11: Orifice plate of a Wurster coater
Applications:
• Preferred for the application of modified release coatings to a wide variety of multi 
particulates.
• And also suitable for drug layering when the drug does is in the low to medium range.
1.6.3.3 Tangential spray coating (Rotor pellet coating):
This  process  is  particularly suitable  for  pellet  powder  coating,  suspension coating  or
film/sugar coating.
In this process the cores are placed on the turntables and hot air is blown upward between
the  turntables  and the granulation area.   The  passage  of  air  causes  the  cores  to  roll  on the
turntables.  At the same time, the coating solution is sprayed on the rolling cores through the
pump and spray gun.  The process involves simultaneous coating and drying of the cores, layer
after layer, until the repeated actions achieve the desired coating thickness or granule size.
Applications:
• Suitable for the application of modified release film coatings to a wide range of multi 
particulate products.
• Ideal for drug layering when the dose is medium to high.
• Also useful as a spheronizing process for producing spheres from powders.
1.7 EXCIPIENTS FOR PELLETS
Formulation  aids  or  excipients  are  added  to  pharmaceutical  dosage  forms  mainly  to
produce satisfactory delivery of the drug to the intended site, to impart favorable characteristics
to the dosage form and to facilitate the manufacture of the product.
Pellets  are to be intended to be administered orally;  the excipients  used in the pellet
dosage forms are typically the same as those used in tablets or capsules formulations. Excipients
are disintegrant, surfactants, pH adjusters, separating agents, spheronization enhancers, glidants
and release modifiers etc. Some examples of such excipients are given. 17,18
             Table No.2: Commonly Used Excipients for pellets
Filler MCC, starch, sucrose, lactose, mannitol
 Binder  Gelatin, HPC, HPMC, MC, PVP, sucrose, starch
 Lubricant  Calcium stearate, glycerine, PEG, Mg. stearate
 Separating agent  Kaolin, talc, silicon dioxide
 Disintegrant  Alginates, croscarmellose sodium
 pH adjuster  Citrate, phosphate, meglumine.
 Surfactant  Polysorbate, SLS
 Spheronization enhancer  MCC , sodium CMC
 Glidant  Talc, starch, Mg stearate.
 Release modifier  Ethyl cellulose, carnauba wax, shellac.
1.8 CAPSULES
Capsules are gelatin shells filled with the ingredients that make up an individual dose.
Dry powders, semi-solids, and liquids that do not dissolve gelatin may be encapsulated. Capsules
account for about 20% of all prescriptions dispensed.
Capsules are available in many different sizes and shapes and can be used for administration of
powders, semisolids and liquids.
1.8.1 Capsules Standards and limits
Description:
It should comply with specifications of product.
Content of active ingredients:
 90 to110% of label claim or as per In house limit.
Uniformity of weight:
                                           Table No.3: Content uniformity limits
Average  weight  of
capsules content
Percentage
deviations allowed
less than 300mg 10%
300mg or more 7.5%
1.9 DISEASE PROFILE20, 21, 28
 1.9.1 OVERACTIVE BLADDER: 
Overactive bladder (OAB) is a condition that results from sudden, involuntary contraction of the
muscle in the wall of the urinary bladder. It is commonly   characterized by urinary urgency, with
or  without  urge  incontinence  usually  with  frequency  and  nocturia.  It  causes  sudden  and
unstoppable need to urinate (urinary urgency),  even though the bladder may contain a small
amount of urine. Overactive bladder, however, should not be considered as normal part of aging.
Overactive bladder is typically caused by spasms of the muscles of the bladder, resulting in an
urge to urinate (hence, urge incontinence). It is primarily a problem of the nerves and muscles of
the bladder. Voluntary control of the sphincter muscles at the opening of the bladder can hold the
urine in the bladder for longer time. Up to 600 cc of urine can be contained in a normal adult
bladder.  Overactive  bladder  typically  results  from  inappropriate  contraction  of  the  detrusor
muscle regardless of the amount of urine. Detrusor is one of the major muscles of the bladder. Its
contraction in response to filling of the bladder by urine is one of the steps in the normal process
of urination. The contraction and relaxation of the detrusor muscle is regulated by the nervous
system. Approximately 300 cc of urine in the bladder can signal the nervous system to trigger
muscles of the bladder to coordinate urination. 
 OAB affects approximately 17% of adults globally. A recent study using current ICS definitions
of OAB found the prevalence of OAB to be 11% in men and 13% in women.28
 1.9.2 Causes of overactive bladder
The common abnormalities of the nervous system that cause overactive bladder are as follows
• Spinal cord injury
• Strokes
• Parkinson’s disease
• Dementia
• Multiple sclerosis
There are also some causes of overactive bladder and urge incontinence with a normal nervous
system. For example, urinary tract infection, bladder stones, or bladder tumors can cause also
cause over activity of the detrusor muscle, leading to overactive bladder.
1.10 Drugs used to treat overactive bladder: 28
Antimuscarinic agents are widely used to treat overactive bladder. Some of the antimuscarnic
drugs used to treat this condition are:
Oxybutinin
Atropine
Tolterodine tartrate 
Ipratropium etc.
                                      
CHAPTER-2
 LITERATURE REVIEW
2.1 Review of literature:
Kreder  et al(2002).  Reported on longterm safety, tolerability and efficacy of extended release
tolterodine in  the  treatment  of  overactive bladder.  They conducted  randomized  double  blind
study in 1377 patients and compared extended release and immediate release dosage forms. They
reported that tolterodine ER 4mg displayed a favourable safety, tolerability and efficacy profile
during 12 months treatment of patients with overactive bladder .33
Vinay  pandit  et  al.(2008) studied  formulation  and  evaluation  of  transdermal  films  for  the
treatment  of  overactive  bladder.  A number  of  the  polymers  like  HPMC,  carbopol-934p  and
ethylcellulose were employed alone or in combination for the preparation of transdermal films.
The films were casted using solvent casting technique. Solutions containing polymer at different
concentrations and polymer at various concentrations were prepared and evaluated for  in vitro
drug  release.  It  was  found  that  polymer  concentration  of  2% was  found  to  be  best  and  if
increased  drug release  was retarded  and 20% concentration of  propylene  glycol  (plasticizer)
shows  less  release.  Among  all  the  formulation  using  HPMC:  Carbopol  (3:1)    with  30%
propylene glycol showed the best release.30 
Lighang zhao et al(2008). Examined the transdermal delivery potential of tolterodine using o -
acymenthol derivatives as the permeation enhancers as well as correlated the enhancing activity
under  in vitro and  in vivo conditions. From the results of  in vitro and  in vivo studies it  was
concluded that (E)-2 isopropyl methylcyclohexyloctadec-9 -enoate(M-OA) is the most promising
enhancer among  O-acyl menthol derivatives for transdermal drug delivery and 2-isopropyl-5-
methyl-cyclohexyl  2-hydroxypanoate (M-LA) produced highest enhancing activity in TOL in
isopropylmyristate solution.31
Kang ten gong et al.(2008) investigated the relationship between formulation variables and drug
release in aqueous ethyl cellulose coating.  Here they studied on the critical  factors and their
influence on the drug release characteristics from an aqueous ethylcellulose barrier membrane
coated  system.  It  was  concluded  that  the  incorporation  of  HPMC or  PVA has  shown to  be
effective in modifying the drug release characteristics  through a surelease barrier  membrane
system.  They  also  reported  that  by  controlling  the  critical  variables  like  pore  former
concentration,  coating  level  and  drug  solubility  the  desired  release  characteristic  can  be
achieved .35
Maria A.F.H  et al.(2010) investigated release mechanisms of theophylline pellets coated with
aqueous ethylcellulose dispersions containing plasticizers and hydroxyl propyl methylcellulose
as  a  water  soluble  pore  former.  Three  different  release  mechanisms  of  pellets  coated  with
aqueous  ethylcellulose  dispersion,  hydroxypropyl  methylcellulose  and  triethylcitrate,  diethyl
phthalate, dibutyl phthalate or dibutyl sebacate are determined. It was found that the drug release
is dependent on the physical state of swollen ethylcellulose and migration of water soluble pore
former respectively.34
Fengying  S.  et  al.(2010)  Prepared and  characterized tolterodine  PLGA microspheres    and
carried  out  pharmacological  evaluation  to  investigate  their  potential  pharmacokinetic  and
pharmacodynamic advantage over tolterodine l-tartarate tablets. They reported that the continued
inhibition of muscarinic receptor of the microspheres formulation might provide a more effective
treatment  of  OAB  patient  than  that  of  the  oral  formulation  which  inhibits  the  receptor
impulsively.32
Namrata et al. (2012) In recent pharmaceutical applications, multiparticulate dosage forms are
gaining  much  importance  over  single-unit  dosage  forms.  The  purpose  of  designing
multiparticulate dosage form is to develop a reliable formulation that has all the advantages of a
single unit formulation and yet devoid of the danger of alteration in drug release profile and
formulation behavior due to unit to unit variation. The aim of present work is qualitative study
on formulation of multiparticulate modified release pellets of Tolterodine Tartrate, by “Wurster
Based  Fluidized  Bed  Coating  Process”(layering  technique).The  main purpose  of  the  present
study was to investigate the feasibility of the wurster process for preparing extended release
pellets and subsequently comparing the release profile of the pellets so prepared with a marketed
reference  product  in  various  media.  Additionally,  the  effects  of  some  independent  process
variables were evaluated. The effect of the various process parameters i.e. inlet air temperature,
product temperature, exhaust temperature, atomization speed, spray pump speed, atomization air
volume and air flow on the Wurster process was studied. The results suggested that the process
parameters greatly vary with the physical properties of the drug, polymers and solvents used in
process for layering of pellets. 36
CHAPTER-3
SCOPE, OBJECTIVE AND
PLAN OF WORK
3.1 Scope of Work
Tolterodine tartrate is an antispasmodic used in the treatment of bladder hyperactivity. It controls
bladder incontinence by controlling contractions. Tolterodine tartrate is a muscuranic receptor
antagonist inhibiting bladder contraction and reducing urinary frequency. The contraindication
factor that prohibit its use include known hypersensitivity, uncontrolled narrow-angle glaucoma,
urinary retention, and gastric retention. 
Tolterodine  is  rapidly absorbed.  Both Tolterodine  and the  5-hydroxymethyl  metabolite  reach
maximal serum concentrations 1-3 hours after dose. The half-life for Tolterodine given as the
tablet is 2-3 hours in extensive metabolizers and about 10 hours in poor metabolizers (devoid of
CYP2D6).  Steady state  concentrations  are reached  within 2  days  after  administration  of  the
tablets. Food does not influence the exposure to the sum of the unbound Tolterodine and the
active 5-hydroxymethyl  metabolite in extensive metabolizers,  although the Tolterodine levels
increase when taken with food
The recommended dose is 2 mg b.i.d. In the case of troublesome side-effects the dose
may be reduced from 2 mg to 1 mg b.i.d. The recommended dose is 1 mg b.i.d. for patients with
impaired renal function, impaired liver function, or receiving concomitant ketoconazole or other
potent  CYP3A4  inhibitors.  Tolterodine  tartrate  is  available  in  market  in  1mg  and  2mg  as
immediate release and 2mg & 4mg as sustained release. 
Hence, in the present study, an attempt has been made to develop the sustained-release
Capsules of Tolterodine tartrate using hydrophobic ethyl cellulose polymer with the addition of a
pore former and a barrier membrane coating and evaluated by in-vitro drug release which will be
comparable to the reference product (Detrol, mfg by Pfizer). The drug release data were plotted
using  various  kinetic  equations  (first-order,  Higuchi’s  kinetics)  to  evaluate  the  drug  release
mechanism and kinetics. In-vivo drug release, biopharmaceutical evaluation, and in-vitro/in-vivo
correlations were beyond the scope of this study and will be considered in future work.
3.2 Objective
 The objective of the present work is to prepare the tolterodine tartrate sustained release
capsules which matches to the reference product 
 To study the effect of different concentration of ethyl cellulose in modifying the drug
release and identify the prototype which matches to the originator.
3.3 PLAN OF WORK
3.3.1 Preformulation Study:
a)  API Characterisation.
b) Drug- Excipient Compatibility Study.
3.3.2 Formulation Development:
a)  Dispensing
b) Preparation of Drug Solution
c) Drug Layering Process (FBP)
d) Film Coating(FBP)
 Preparation of Film Coating Solution
 Coating Process 
e) Coating (FBP)
 Preparation of Coating Solution
 Coating Process 
f) Sifting
g) Capsule Filling
3.3.3 Evaluation
a) Evaluation Tests For Drug Loaded Tolterodine Tartrate Pellets
 Physical Description
 Sieve Analysis
 Water content by KF titration
b) Evaluation Tests For Capsule Containing Pellets
 Weight Variation Tests
 Content Uniformity
 Lock Length
 Assay by HPLC
 Dissolution by HPLC
3.3.4 Stability studies
CHAPTER-4
MATERIALS AND EQUIPMENTS
4.1 Instruments and Equipments Used 
S.No. t Instruments Make and Model
1. Weighing balance Sartorius(CP225D)
2. Mechanical stirrer Vision labs
3. Tapped density apparatus Electro lab (ETD-1020)
4. Fluidized bed processor Umang
5. Dissolution test system Electrolab
6. HPLC Shimadzu(LC2010CH)
7. Automatic capsule filling machine Rimek formulations
8. IR Spectroscopy Bruker
Table:4  List of instruments/equipments used
4.2 LIST OF MATERIALS USED
S.No Ingredients Manufacturer
1 Sugar spheres Degussa, Mumbai
2 Tolterodine Tartrate Rachem pharma ltd
3 HPMC 6cps Colorcon Asia Pvt Ltd, Goa
4 Talc Luzenac Pharma, Italy
5 Ethyl Cellulose N-50 Colorcon Asia Pvt Ltd, Goa
6 PVP K30 ISP
7 PEG 6000 Clariant Inc, USA
8 Isopropyl alcohol Rachem pharma ltd
9 Purified water Rachem pharma ltd
Table: 5 List of Materials used
4.3 Drug profile: 28
Generic Name: Tolterodine tartarate
Chemical  Name:  (R)-N,N-diisopropy-3-(2-hydroxy-5-methylphenyl)-3-phenyl  propanamine
hydrogen tartrate
Chemical Formula: C26H37NO7
Molecular weight: 475.6 gm/mol
Structure of Tolterodine tartrate:
Category: Competitive muscarinic receptor antagonist.
Solubility: Very  soluble  in  water,  soluble  in  methanol,  slightly  soluble  in  ethanol,  and
practically insoluble in toluene.
Melting Point:  205o C
Mechanism of action: Tolterodine is a competitive muscarinic receptor antagonist. Both urinary
bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral
administration,  tolterodine  is  metabolized  in  the  liver,  resulting  in  the  formation  of  the  5-
hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl
metabolite, which exhibits an anti-mucarinic activity similar to that of tolterodine, contributes
significantly to the therapeutic effect.
Pharmacokinetics: 20,21,28
Tolterodine is  rapidly absorbed.  Both tolterodine and the 5-hydroxymethyl  metabolite  reach
maximal serum concentrations 1-3 hours after dose. The half-life for tolterodine given as the
tablet is 2-3 hours in extensive metabolizers and about 10 hours in poor metabolizers (devoid of
CYP2D6).  Steady state concentrations are reached within 2 days  after administration of the
tablets. Food does not influence the exposure to the sum of the unbound tolterodine and the
active 5-hydroxymethyl  metabolite in extensive metabolizers,  although the tolterodine levels
increase when taken with food. Clinically relevant changes are likewise not expected in poor
metabolizers.
Absorption:
After oral administration tolterodine is subject to CYP2D6 catalyzed first-pass metabolism in
the  liver,  resulting  in  the  formation  of  the  5-hydroxymethyl  derivative,  a  major
pharmacologically  active  metabolite.  The  absolute  bioavailability  of  tolterodine  is  17%  in
extensive metabolizers, the majority of the patients, and 65% in poor metabolizers (devoid of
CYP2D6).
Distribution:
Tolterodine and the 5-hydroxymethyl metabolite bind primarily to alpha-1-acid glycoprotein.
The  unbound  fractions  are  3.7%  and  36%,  respectively.  The  volume  of  distribution  of
tolterodine is 113 L.
Metabolism:
Tolterodine  is  extensively  metabolized  by  the  liver  following  oral  dosing.  The  primary
metabolic route is mediated by the polymorphic enzyme CYP2D6 and leads to the formation of
the 5-hydroxymethyl metabolite. The half-life of the 5-hydroxymethyl metabolite is 3-4 hours.
Further metabolism leads to formation of 5-carboxylic acid and N-dealkylated 5-carboxylic acid
metabolites,  which  account  for  51  % and  29  % of  the  metabolites  recovered  in  the  urine,
respectively. A subset (about 7%) of the population is devoid of CYP2D6 activity. The identified
pathway of metabolism for these individuals (poor metabolizers) is de-alkylation via CYP3A4
to N-dealkylated tolterodine, which does not contribute to the clinical effect. The remainder of
the population is referred to as extensive metabolizers. The systemic clearance of tolterodine in
extensive metabolizers is  about 30 L/h.  In  poor metabolizers the reduced clearance leads to
significantly  higher  serum  concentrations  of  tolterodine  (about  7-fold)  and  negligible
concentrations of the 5-hydroxymethyl metabolite are observed.
The 5-hydroxymethyl metabolite is pharmacologically active. Because of the differences in the
protein-binding characteristics of tolterodine and the 5-hydroxymethyl metabolite, the exposure
(AUC) of  unbound tolterodine  in  poor metabolizers  is  similar  to  the  combined  exposure  of
unbound tolterodine and the 5-hydroxymethyl metabolite in patients with CYP2D6 activity given
the same dosage regimen. The safety, tolerability and clinical response are similar irrespective of
phenotype.
Elimination:
The excretion of radioactivity after administration of 14C-tolterodine is about 77% in urine and
17% in faeces. Less than 1% of the dose is recovered as unchanged drug, and about 4% as the 5-
hydroxymethyl  metabolite.  The  carboxylated  metabolite  and  the  corresponding  dealkylated
metabolite account for about 51% and 29% of the urinary recovery, respectively.
Indications and usage:
Tolterodine tartrate is indicated for the treatment of overactive bladder with symptoms of urinary
urgency, frequency  and/or urge incontinence.
Dosage and administration:
The recommended dose is 2 mg b.i.d. In the case of troublesome side-effects the dose may be
reduced  from 2 mg to  1  mg b.i.d.  The  recommended  dose  is  1  mg b.i.d.  for  patients  with
impaired renal function, impaired liver function, or receiving concomitant ketoconazole or other
potent CYP3A4 inhibitors. After six months the need for further treatment should be considered.
Safety and effectiveness in children have not been established.
Contraindications:
Tolterodine is contraindicated in patients with:
• Known hypersensitivity to Tolterodine or any other component of the drug.
• Urinary retention
• Uncontrolled narrow angle glaucoma.
Warning and Precautions:
Tolterodine Tartrate should be used with caution in following patients:
• At risk for urinary retention.
• At risk for decreased gastro intestinal motility.
• With impaired renal function.
• With impaired hepatic function
• With myasthenia gravis.
Storage:
Store in a tightly closed container.
4.4.EXCIPIENT PROFILE17,18
4.4.1. Ethyl cellulose
Nonproprietary Names
• BP: Ethyl cellulose
• PhEur: Ethyl cellulosum
• USPNF: Ethyl cellulose
• Synonyms: Aquacoat ECD; Aqualon; E462; Ethocel; Surelease.
Chemical Name: Cellulose ethyl ether
Empirical Formula and Molecular Weight: Ethylcellulose with complete ethoxyl substitution
(DS = 3) is
C12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a wide variety of molecular weights.
Ethyl cellulose, an ethyl ether of cellulose, is a long-chain polymer of β-anhydroglucose units
joined together by actual linkages.
Structural Formula
Functional Category:  Coating agent;  flavoring fixative; tablet binder; tablet filler;  viscosity-
increasing agent.
Description: Ethyl cellulose is a tasteless, free-flowing, white to light tan-colored powder.
Applications in Pharmaceutical Formulation or Technology: Ethyl cellulose is widely used in
oral and topical pharmaceutical formulations;
Table 6 : Uses of Ethyl cellulose.
Use Concentration (%)
Microencapsulation 10.0–20.0
Use Concentration (%)
Sustained-release tablet coating 3.0–20.0
Tablet coating 1.0–3.0
Tablet granulation 1.0–3.0
 The main use of ethyl cellulose in oral formulations is as a hydrophobic coating agent for
tablets and granules. Ethyl cellulose coatings are used to modify the release of a drug, to
mask an unpleasant taste, or to improve the stability of a formulation; for example, where
granules  are  coated  with  ethyl  cellulose  to  inhibit  oxidation.  Modified-release  tablet
formulations may also be produced using ethyl cellulose as a matrix former.
 Ethyl cellulose, dissolved in an organic solvent or solvent mixture, can be used on its own
to produce water-insoluble films. Higher-viscosity ethyl cellulose grades tend to produce
stronger and more durable films. Ethyl cellulose films may be modified to alter their
solubility,  by  the  addition  of  hypromellose  or  a  plasticizer;  An  aqueous  polymer
dispersion (or  latex) of ethyl  cellulose such as  Aquacoat  ECD (FMC Biopolymer) or
Surelease (Colorcon) may also be used to produce ethyl cellulose films without the need
for organic solvents.
 Drug release through ethylcellulose-coated dosage forms can be controlled by diffusion
through the film coating. This can be a slow process unless a large surface area (e.g.
pellets or granules compared with tablets) is utilized. In those instances, aqueous ethyl
cellulose dispersions are generally used to coat granules or pellets. Ethyl cellulose-coated
beads  and  granules  have  also  demonstrated  the  ability  to  absorb  pressure  and  hence
protect the coating from fracture during compression.
 High-viscosity grades of ethyl cellulose are used in drug microencapsulation.
 Release of a drug from an ethyl cellulose microcapsule is a function of the microcapsule
wall thickness and surface area.
 In tablet formulations, ethyl cellulose may additionally be employed as a binder, the ethyl
cellulose being blended dry or wet-granulated with a solvent such as Ethanol  (95%).
Ethyl cellulose produces hard tablets with low friability, although they may demonstrate
poor dissolution.
 Ethyl cellulose has also been used as an agent for delivering therapeutic agents from oral
(e.g. dental) appliances.
In topical formulations, ethyl cellulose is used as a thickening agent in creams, lotions, or gels,
providan  appropriate  solvent  is  used.  Ethyl  cellulose  has  been  studied  as  a  stabilizer  for
emulsions. 17,18
4.4.2. Hypromellose
Nonproprietary Names:
• BP: Hypromellose
• JP: Hydroxypropylmethylcellulose
• PhEur: Hypromellosum
• USP: Hypromellose
Synonyms:
Benecel  MHPC; E464;  hydroxypropyl  methylcellulose;  HPMC;  Methocel;  methylcellulose
propylene glycol ether; methyl hydroxypropylcellulose; Metolose; Tylopur.
Chemical Name:
Cellulose hydroxypropyl methyl ether
Empirical Formula and Molecular Weight:
Hypromellose defined in the USP 28 specifies the substitution type by appending a four-digit
number to the nonproprietary name: e.g., hypromellose 1828. The first two digits refer to the
approximate percentage content of the methoxy group (OCH3). The second two digits refer to the
approximate percentage content of the hydroxypropoxy group (OCH2CH(OH)CH3), calculated
on a dried basis.. Molecular weight is approximately 10 000–1 500 000. The JP 2001 includes
three separate monographs for hypromellose:  hydroxypropylmethylcellulose 2208, 2906, and
2910, respectively.
Structural Formula:
Where R is H, CH3, or CH3CH(OH)CH2
Functional Category:
Coating  agent;  film-former;  rate-controlling  polymer  for  sustained  release;  stabilizing  agent;
suspending agent; tablet binder; viscosity-increasing agent.
Applications in Pharmaceutical Formulation or Technology:
 Hypromellose  is  widely  used  in  oral,  ophthalmic  and  topical  pharmaceutical
formulations.
 In oral products, Hypromellose is primarily used as a tablet binder, in film-coating, and as
a matrix for use in extended-release tablet formulations. Concentrations between 2% and
5% w/w may be used  as  a  binder  in  either  wet-  or  dry-granulation processes.  High-
viscosity grades may be used to retard the release of drugs from a matrix at levels of 10–
80% w/w in tablets and capsules.
 Depending upon the viscosity grade, concentrations of 2–20% w/w are used for film-
forming solutions to film-coat tablets. Lower-viscosity grades are used in aqueous film-
coating solutions, while higher-viscosity grades are used with organic solvents. Examples
of film-coating materials that are commercially available include AnyCoat C, Spectracel,
and Pharmacoat.
 Hypromellose is also used as a suspending and thickening agent in topical formulations.
Compared  with  methylcellulose,  hypromellose  produces  aqueous  solutions  of  greater
clarity, with fewer undispersed fibers present, and is therefore preferred in formulations
for  ophthalmic use.  Hypromellose at  concentrations  between 0.45–1.0% w/w may be
added as a thickening agent to vehicles for eye drops and artificial tear solutions.
 Hypromellose is also used as an emulsifier, suspending agent, and stabilizing agent in
topical gels and ointments. As a protective colloid, it can prevent droplets and particles
from coalescing or agglomerating, thus inhibiting the formation of sediments.
 In addition, hypromellose is used in the manufacture of capsules, as an adhesive in plastic
bandages,  and  as  a  wetting  agent  for  hard  contact  lenses.  It  is  also  widely used  in
cosmetics and food products.
Description:
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular powder.17,18
4.4.3.IPA
Nonproprietary Names:
• BP: Isopropyl alcohol
• JP: Isopropanol
• PhEur: Alcohol isopropylicus
• USP: Isopropyl alcohol
Synonyms:
Dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; sec-propyl alcohol.
Chemical Name:
Propan-2-ol
Empirical Formula and Molecular Weight:
C3H8O,60.1
Structural Formula:
Functional Category:
Disinfectant; solvent.
Applications in Pharmaceutical Formulation or Technology:
 Isopropyl  alcohol (propan-2-ol)  is  used in cosmetics and pharmaceutical  formulations
primarily as a solvent in topical formulations. It is not recommended for oral use owing
to its toxicity;
 Although it is used in lotions, the marked degreasing properties of isopropyl alcohol may
limit its usefulness in preparations used repeatedly. Isopropyl alcohol is also used as a
solvent  both  for  tablet  film-coating  and  for  tablet  granulation,  where  the  isopropyl
alcohol is subsequently removed by evaporation. It has also been shown to significantly
increase the skin permeability of nimesulide from carbomer 934.
 Isopropyl alcohol has some antimicrobial activity and a 70% v/v aqueous solution is used
as a topical disinfectant. Therapeutically, isopropyl alcohol has been investigated for the
treatment of postoperative nausea or vomiting.
Description:
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a characteristic,
spirituous odor resembling that  of  a mixture of  Ethanol  and acetone;  it  has  a  slightly bitter
taste.17,18
4.4.4. PEG
Nonproprietary Names:
• BP:   Macrogols
• JP:   Macrogol 400
• Macrogol 1500
• Macrogol 4000
• Macrogol 6000
• Macrogol 20000
• PhEur:   Macrogola
• USPNF:   Polyethylene glycol
Synonyms:
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; PluriolE;polyoxyethylene glycol.
Chemical Name:
α-Hydro-ω-hydroxypoly(oxy-1,2-ethanediyl) [25322-68-3]
Empirical Formula and Molecular Weight:
HOCH2(CH2OCH2)mCH2OH where m represents the average number of oxyethylene groups.
Alternatively,  the  general  formula  H(OCH2CH2)nOH may be  used  to  represent  polyethylene
glycol, where n is a number m in the previous formula + 1.
The number that follows PEG indicates the average molecular weight of the polymer.
Structural Formula:
Functional Category:
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology:
 Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical formulations
including parenteral, topical, ophthalmic, oral, and rectal preparations. It has been used
experimentally in biodegradable polymeric matrices used in controlled-release systems.
 Polyethylene glycols are stable, hydrophilic substances that are essentially nonirritant to
the skin; They do not readily penetrate the skin, although the polyethylene glycols are
water-soluble and are easily removed from the skin by washing, making them useful as
ointment  bases.  Solid  grades  are  generally  employed  in  topical  ointments,  with  the
consistency of the base being adjusted by the addition of liquid grades of polyethylene
glycol.
 Mixtures of polyethylene glycols can be used as suppository bases, for which they have
many advantages over fats. For example, the melting point of the suppository can be
made  higher  to  withstand  exposure  to  warmer  climates;  release  of  the  drug  is  not
dependent  upon  melting  point;  the  physical  stability  on  storage  is  better;  and
suppositories  are  readily  miscible  with  rectal  fluids.  Polyethylene  glycols  have  the
following disadvantages:  they are  chemically more  reactive  than  fats;  greater  care  is
needed in processing to avoid inelegant contraction holes in the suppositories; the rate of
release of water-soluble medications decreases with the increasing molecular weight of
the polyethylene glycol; and polyethylene glycols tend to be more irritating to mucous
membranes than fats.
 Aqueous polyethylene glycol solutions can be used either  as  suspending agents  or to
adjust  the  viscosity  and  consistency  of  other  suspending  vehicles.  When  used  in
conjunction with other emulsifiers, polyethylene glycols can act as emulsion stabilizers.
 Liquid polyethylene glycols are used as water-miscible solvents for the contents of soft
gelatin capsules. However, they may cause hardening of the capsule shell by preferential
absorption of moisture from gelatin in the shell.
 In concentrations up to approximately 30% v/v, PEG 300 and PEG 400 have been used as
the vehicle for parenteral dosage forms.
Description:
Liquid  grades  (PEG  200–600)  occur  as  clear,  colorless  or  slightly  yellow-colored,  viscous
liquids. They have a slight but characteristic odor and a bitter, slightly burning taste. PEG 600
can occur as a solid at ambient temperatures.
Solid grades (PEG>1000) are white or off-white in color, and range in consistency from pastes to
waxy flakes. They have a faint, sweet odor. Grades of PEG 6000 and above are available as free-
flowing milled powders. 17,18
4.4.5. Talc
Nonproprietary Names
• BP: Purified talc
• JP: Talc
• PhEur: Talcum
• USP: Talc
Synonyms
Altalc;  E553b;  hydrous  magnesium  calcium  silicate;  hydrous  magnesium  silicate;  Luzenac
Pharma;  magnesium hydrogen  metasilicate;  Magsil  Osmanthus;  Magsil  Star;  powdered  talc;
purified French chalk; Puretalc; soapstone; steatite; Superiore.
Chemical Name
Talc
Empirical Formula and Molecular Weight
Talc is a purified, hydrated, magnesium silicate, approximating to the formula Mg6(Si2O5)4(OH)4.
It may contain small, variable amounts of aluminum silicate and iron.
Functional Category
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
Table 7: Uses of talc
Use Concentration (%)
Dusting powder 90.0–99.0
Glidant and tablet lubricant 1.0–10.0
Tablet and capsule diluent 5.0–30.0
 Although today it is less commonly used. However, it  is widely used as a dissolution
retardant  in  the  development  of  controlled-release  products.  Talc  is  also  used  as  a
lubricant in tablet formulations; in a novel powder coating for extended-release pellets;
and as an adsorbant.
 In topical preparations, talc is used as a dusting powder, although it should not be used to
dust  surgical  gloves;  Talc  is  a  natural  material;  it  may  therefore  frequently  contain
microorganisms and should be sterilized when used as a dusting powder.
 Talc  is  additionally  used  to  clarify  liquids  and  is  also  used  in  cosmetics  and  food
products, mainly for its lubricant properties.
Description
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline powder. It
adheres readily to the skin and is soft to the touch and free from grittiness. 17,18
4.4.6. Sugar Spheres
Nonproprietary Names
• BP: Sugar spheres
• PhEur: Saccharispheri
• USPNF: Sugar spheres
Synonyms
Non-pareil; non-pareil seeds; NPTAB; Nu-Core; Nu-Pareil PG; sugar seeds; Suglets.
Functional Category
Tablet and capsule diluent.
Applications in Pharmaceutical Formulation or Technology
 Sugar  spheres  are  mainly  used  as  inert  cores  in  capsule  and  tablet  formulations,
particularly  multiparticulate  sustained-release  formulations.  They form the  base  upon
which a drug is coated, usually followed by a release-modifying polymer coating.
 Alternatively, a drug and matrix polymer may be coated onto the cores simultaneously.
The active  drug is  released  over  an  extended  period either  via  diffusion through the
polymer or through to the controlled erosion of the polymer coating.
 Complex  drug  mixtures  contained  within  a  single-dosage  form  may be  prepared  by
coating  the  drugs  onto  different  batches  of  sugar  spheres  with  different  protective
polymer coatings.
 Sugar spheres are also used in confectionery products.
Description
The  USPNF  23  describes  sugar  spheres  as  approximately  spherical  granules  of  a  labeled
nominal-size range with a uniform diameter and containing not less than 62.5% and not more
than 91.5% of sucrose, calculated on the dried basis. The remainder is chiefly starch.
The PhEur 2005 states that sugar spheres contain not more than 92% of sucrose calculated on the
dried  basis.  The  remainder  consists  of  corn  (maize)  starch  and  may  also  contain  starch
hydrolysates and color additives. The diameter of sugar spheres varies from 200 to 2000 µm and
the upper and lower limits of the size of the sugar spheres are stated on the label. 17,18
4.4.7. Water
Nonproprietary Names
• BP: Purified water
• JP: Purified water
• PhEur: Aqua purification
• USP: Purified water
Synonyms
Aqua; hydrogen oxide.
Chemical Name
Water
Empirical Formula and Molecular Weight
H2O, 18.02
Functional Category
Solvent.
Applications in Pharmaceutical Formulation or Technology
 Water  is  the  most  widely  used  excipient  in  pharmaceutical  production  operations.
Specific grades of water are used for particular applications in concentrations up to 100%
Table 8 : Applications of specific grades of water.
Type Use
Bacteriostatic  water
for injection
Diluent for ophthalmic and multiple-dose injections.
Potable water Public supply suitable for drinking, the purity of which is unlikely to be
suitable for use in the manufacture of pharmaceuticals.
Purified water Vehicle  and  solvent  for  the  manufacture  of  drug  products  and
pharmaceutical  preparations; not  suitable for use in the manufacture of
parenteral products.
Sterile  water  for
inhalation
Diluent for inhalation therapy products.
Sterile  water  for
injection
Diluent for injections.
Type Use
Sterile  water  for
irrigation
Diluent for internal irrigation therapy products.
Water  for  injections
in bulk
Water for the bulk preparation of medicines for parenteral administration.
 Purified  water  and  water  for  injection  are  also  used  for  cleaning  operations  during
production of pharmaceutical products.
Description
The term ‘water’ is used to describe potable water that is freshly drawn direct from the public
supply and is suitable for drinking. The chemical composition of potable water is variable and
the nature and concentrations of the impurities in it depend upon the source from which it is
drawn. Although potable water must be both palatable and safe to drink, for most pharmaceutical
applications potable water is purified by distillation, ion exchange treatment, reverse osmosis, or
some other  suitable process to produce ‘purified water’.  For  certain  applications,  water  with
pharmacopeial specifications differing from those of purified water should be used, e.g. water for
injection; Water is a clear, colorless, odorless, and tasteless liquid.
CHAPTER-5
                         METHADOLOGY
5.1. Analytical Method Development
5.1.1. Scanning of λ max:
Preparation of stock solution (1mg/ml): 100mg of Tolterodine was dissolved in 10ml of methanol
in a 100ml standard flask and this solution was made upto 100ml with methanol.
For the selection of analytical wavelength, 10 µg/ml solution of Tolterodine was prepared by
appropriate dilution of standard stock solution and scanned in the spectrum mode from 200 nm
to 400 nm.
5.1.2. Preparation of standard curve:
The standard curve was established by preparing a stock solution(1mg/ml). 100mg of Tolterodine
was dissolved in 10ml of methanol in a 100ml standard flask and this solution was made upto
100ml with methanol. From the stock solution 10ml solution was transferred to a 100ml standard
flask and volume was made upto 100ml with methanol. 
From the above prepared solution 10ml was transferred to a 100ml standard flask and volume
was made upto 100ml with methanol. This was used as the working stock solution. From the
working stock solution different concentrations ranging between 5 to 25 µg/ml were prepared.
Absorbance was determined by using UV spectrophotometer.
From this data, the standard curve of Tolterodine was obtained by plotting absorbance on Y-axis
against concentration on X-axis.
5.2. Preformulation Studies
5.2.1 API Characterization:
The overall objective of preformulation testing is to generate information useful in developing
the formulation which is stable and bioavailable. Further the use of preformulation parameters
maximizes the chances in formulating an acceptable, safe, efficacious and stable product. For
any drug substance to formulate into a dosage form, it is necessary to study the physicochemical
properties  of  the  bulk  drug  like  physical  appearance,  solubility,  melting point,  particle  size,
compatibility.
5.2.1.a. Physical Appearance:
The appearance of the API was done by visual observation. The content was observed visually
for compliance against the specification.
5.2.1.b.Solubility Studies:
The  solubility  of  drug  is  an  important  physicochemical  property  because  it  affects  the
bioavailability of the drug, the rate of drug release into the dissolution medium, and consequently
the therapeutic efficacy of the pharmaceutical product. The solubility of a material is usually
determined by the equilibrium solubility method,  which employs  a  saturated solution of  the
material, obtained by stirring an excess of material in the solvent for a prolonged period until
equilibrium is achieved. 
5.2.1.c.Sieve Analysis:
The main aim of sieve analysis is to determine the different size of drug particles present. A
series of standard sieve are stacked one above the other so that sieves with larger pore size (less
sieve number) occupy top position followed by sieves  with  smaller pore size (greater sieve
number towards the bottom).
Procedure:
A series of sieves were arranged in the order of their decreasing pore diameter (increasing sieve
number) such as sieve number 20, 30, 40, 60, 100 and 200. 100 grams of drug was weighed
accurately and transferred to sieve number 20 which were kept on top. The sieves were shaken
for about 5-10 minutes. Then the drug retained on each sieves was taken, weighed separately and
amount retained was expressed in terms of percentage.
5.2.2. Drug - Excipient Compatibility Studies:
Compatibility studies were carried out to study the possible interactions between Tolterodine
Tartrate and other inactive ingredients. 
Procedure:
The compatibility studies were carried out by taking a mixture of drug and excipients at the ratio
in which they are expected to be present in the innovator product. A part of mixture was exposed
to different storage conditions like 40 oC±2oC /75% RH ±5% RH and control samples were kept
at 2-8 oC. They were tested with respect to their physical and chemical aspects. These samples
were collected at regular intervals and subjected to Differential Scanning Calorimetry.
                Table 9: Conditions for compatibility studies
S.No. Storage Condition Samples packed  in Sampling Periods
1
Accelerated
40 oC±2oC /75% RH ±5%
RH
3 Double polythene
bags
1, 2, 3, 4 Weeks
2 Refrigeration   2-8oC
1 Double polythene
bag + 1 glass vessel
1, 2, 3, 4 Weeks
FT-IR Spectrophotometric Method:
Potassium Bromide (KBr) pellet method was employed .  KBr was dried in oven at 45 °C before
analysis. The pure drug was triturated with KBr and pellet was prepared by setting the pressure
to 100 kg/cm2 for 2 minutes. The obtained pellet was analyzed in FTIR 8400 S, Shimadzu, Japan.
KBr background was obtained initially before analysis of test samples. The same procedure was
repeated for analysis of drug and HPMC E5, HPMC K4M, also drug and excipient mixture free
from moisture content were used for analysis.37
5.3 Method of Manufacture8, 15, 22
Dispensing
The dispensing of  Active Pharmaceutical  Ingredient  and Excipients is carried out as per  the
manufacturing formula.
Preparation Of Drug Solution :
Disperse Tolterodine Tartrate in purified water continuous stirring till a uniform suspension is
obtained.  Hypromellose  and  talc  were  dissolved  in  purified  water  and  stirred  until  a  clear
solution is obtained. HPMC and talc solution was transferred into the drug solution and were
continuously stirred until a uniform suspension was obtained. 
Drug Layering Process (FBP)
Sugar spheres (20#-25#) were loaded into FBP bowl. The sugar spheres were coated by bottom
spray wruster at peristaltic pump rpm of 25-100 and atomizing air pressure of 2.0-5.0 Kg/cm2 till
the coating solution was completed.  The drug solution was sprayed completely and after the
completion of drug solution the fluidization level was reduced and drying was done for 10-15
minutes. The drug layered pellets were unloaded from FBP, sifted and readied for Film coating.
Barrier Coating (FBP) 23,25
Preparation Of Barrier Coating Solution:
Hypromellose was dissolved in purified water with continuous stirring until a uniform solution
was obtained. 
Coating Process
The drug loaded pellets (18#-20#) were loaded into FBP bowl. The drug loaded pellets were
coated by bottom spray wruster at peristaltic pump rpm of 15-20 and atomizing air pressure of
2.0-5.0  Kg/cm2  till  the  coating  solution  was  completed.  The  coating  solution  was  sprayed
completely and after  the completion of drug solution the fluidization level  was reduced and
drying was done for 10-15 minutes. The drug layered pellets were unloaded from FBP, sifted and
readied for EC coating.
SR Coating (FBP) 
Preparation Of Coating Solution :
Ethyl cellulose, Povidone and Talc were dispersed in Isopropyl Alcohol with continuous stirring
till a uniform suspension was obtained. Polyethylene glycol was dissolved in purified water and
stirred to get a clear solution. The EC solution was transferred into the PEG in water solution and
was continuously stirred until a uniform suspension was obtained.
Coating  Process
The drug loaded pellets (18#-20#) were loaded into FBP bowl. The drug loaded pellets were
coated by bottom spray wruster at peristaltic pump rpm of 15-20 and atomizing air pressure of
2.0-5.0  Kg/cm2  till  the  coating  solution  was  completed.  The  coating  solution  was  sprayed
completely and after  the completion of drug solution the fluidization level  was reduced and
drying was done for 10-15 minutes. The drug layered pellets were unloaded from FBP and were
sifted prior to be filled in capsules.
Sifting
Sift the coated dried pellets through the #18 and collect retains and downs separately.
Sift the #18 passing pellets through #20 and collect retains and passing separately 
Capsule Filling
The fill weight of 200 mg is checked and filled in size “3”capsule in the capsule filling machine.
Table 10: FBP parameters
S.No. Parameters Specifications
1 Atomizing air pressure (kg/cm2) 2.0-5.0
2 Inlet temperature (°c) (40-50)
3 Bed temperature (°c) (40-45)
4 Peristaltic pump rpm 25-100
S.No
Ingredie
nts(mg)
Quantity 
Trial
I
Trial
II
Trial
III
Trial
IV
Trial
V
Trial
VI
Trial
VII
Trial
VIII
Drug Loading
1
Sugar
Spheres 
171 172 174 170 171 171 171 174
2
Tolterodi
ne
Tartrate
4 4 4 4 4 4 4 4
3 HPMC 6 6 6 6 6 6 6 6
6cps
4 Talc 2 2 2 2 2 2 2 2
5
Purified
water
Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Barrier Coating
6
HPMC
6cps
--- --- --- 5.5 5 4.5 4 3
7
Purified
water
--- --- --- Q.S Q.S Q.S Q.S Q.S
SR Coating
8
Ethyl
Cellulose
N-50
12 11 9 8 7.5 7 6.5 6
9 PVP K30 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6
10
PEG
6000
1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4
11 Talc 2 2 2 2 2 2 2 2
12 IPA Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
13
Purified
water
Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
TABLE 11 : Formulation of Tolterodine Tartrate Core Pellets
5.4. Evaluation
A. Evaluation Tests For Drug Loaded Tolterodine Tartrate Pellets:
5.4.1. Physical Description:
0.5g of pellets were transferred into a dry petri dish or dispensed on a white card. The content
was visually observed for compliance against specification. 
5.4.2. Sieve Analysis:
The particle size of the pellets after drug loading wass evaluated by mechanical sieving using a
series of sieves with aperture size 1, 0.85, 0.71, 0.60mm. A sample load of 100g was placed on
the sieve and shaken by mechanical shaker. The weight of pellets retained on each sieve was
determined and mean particle size was determined.
5.4.3. Water Content by KF Titration:
 30ml of methanol was taken in a clean, dried Karl Fischer titration flask and titrated with KF
reagent  until  the  end  point  to  neutralize  the  free  water.  Tolterodine  Tartrate  pellets  were
powdered finely. Accurately weighed quantity of 0.5gm of sample was transferred to the titration
flask and dissolved by stirring and titrated with KF reagent to the end point and percentage water
content was calculated by following formula. 
% Water Content = V×F×100/W×100
Where,    V = Volume of KF reagent consumed by sample
F = Factor for KF reagent
W = Weight of sample in grams.
B. Evaluation Tests For Capsules Containing Pellets:
5.4.4. Weight Variation Test:
            20 intact  capsules were selected randomly and weighed and average weight was
calculated. Individual weight of each capsule was determined. According to USP, none of the
individual capsule weight should be less than 90% and more than 110% of the average weight.
5.4.5. Content Uniformity:
According to USP, 30 intact capsules were selected, of which 10 were assayed. 9 of 10 capsules
should be within the potency range of 85%-115%. The potency of  10th capsule should not exceed
the range of 75-125%.
5.4.6. Lock Length:
The lock length can be determined by vernier callipers. The empty capsule cap and body were
measured individually to know the lock length of the capsule.
5.4.7. Assay by HPLC :
Reagents:
Potassium dihydrogen orthophosphate      : AR Grade
Triethylamine                                             : AR Grade
Acetonitrile                                                 : HPLC Grade
Methanol         : HPLC Grade
Water          : Milli-Q-Grade
Chromatographic Conditions:
Column                              : Develosil C18, 250mm x 4.6mm x 5µm or its equivalent
Flow Rate                          : 1.0 ml/min
Wave Length                     : 215 nm
Column Temperature         : 25°C
Injection Volume               : 100 µL
Run Time                           : 12 minutes.
Preparation of Mobile Phase:
 About 2.0g of potassium hydrogen phosphate was weighed and dissolved in 425 ml of water.
400 ml of methanol and 175 ml of acetonitrile were added. pH of the solution was adjusted to
7.2 with Triethylamine. Solution was filtered and degassed.
Preparation of Standard Solution:
Accurately  weighed  quantity  of  about  25mg  of  Tolterodine  Tartrate  working  standard  was
transferred  into  50ml  volumetric  flask.  20  ml  of  methanol  was  added  and  sonicated  for  10
minutes and diluted with methanol to make up the volume. It was mixed and filtered. 2 ml of this
solution was transferred to a 100ml volumetric flask and diluted with mobile phase to the make
up the volume and mixed.
Preparation of Sample Solution:
Accurately weighed quantity of powdered pellets equivalent to 25mg of Tolterodine Tartrate was
transferred into 250ml volumetric flask, 150ml of mobile phase was added and sonicated for 30
minutes and solution was cooled to room temperature. This was diluted with mobile phase to
make up the volume, mixed and filtered. 5ml of this solution was transferred to 50ml volumetric
flask and diluted with mobile phase to make up the volume and mixed.
System Suitability:
The peak responses are recorded for standard preparation and sample preparation. The relative
standard deviation for six replicate standard solution injections should not be more than 2%. The
tailing factor for Tolterodine Tartrate peak should not be more than 2.0. Theoretical plates for
Tolterodine Tartrate peak should not be less than 2000.
Procedure:
100µl, six replicate injections of standard solution and single injection of sample solution were
injected. The chromatograms are recorded and the peak response was measured. The assay (in
%) was calculated by using following formula.
                                  AT     WS     2       250      50       P           100
%Drug Content = ------x-------x-----x--------x-----x------x-------------------x100
                                  AS     50     100      WT        5     100     Label claim
Where,
AT  = Peak area of Tolterodine Tartrate in sample solution
AS  = Average peak area of Tolterodine Tartrate in standard solution
WS  =Amount of Tolterodine Tartrate taken in working standard (mg)
WT  =Amount of sample (mg)
P    = Potency of Tolterodine Tartrate working standard used.
5.4.8. Dissolution by HPLC :
Chromatographic Conditions:
Column                              : Develosil C18, 250mm x 4.6mm x 5µm or its equivalent
Flow Rate                          : 1.0 ml/min
Wave Length                     : 215 nm
Column Temperature         : 25°C
Injection Volume               : 100 µL
Run Time                           : 12 minutes.
Dissolution Parameters:
Medium                             : 900ml of pH 6.8 phosphate buffer
Apparatus        : USP Type I (Basket)
RPM                                   : 100
Temperature                       : 37 ± 0.5ºC
Time Intervals                    : 1st Hour, 2nd Hour, 4th Hour and 8th Hour.
Preparation of Dissolution medium:
6.8g of potassium hydrogen ortho phosphate was dissolved  in 1000ml water. pH was adjusted to
6.8±0.5 with 2N Sodium hydroxide or 2N Hydrochloric acid.
Preparation of Mobile Phase:
 2.0g of potassium hydrogen phosphate was weighed and dissolved in 425 ml of water. 400 ml of
methanol and 175mL of acetonitrile was added. The pH of the solution was adjusted to 7.2 with
Triethylamine, filtered and degased.
Preparation of Standard Solution:
Accurately  weighed  quantity  of  about  25mg  of  Tolterodine  Tartrate  working  standard  was
transferred  into  50ml  volumetric  flask.  20  ml  of  methanol  was  added  and  sonicated  for  10
minutes and diluted with methanol to make up the volume, mixed and filtered.  1 ml of this
solution was transferred to a 100ml volumetric flask, diluted with mobile phase to the make up
the volume and mixed.
Preparation of Sample Solution:
The  pellets  equivalent  to  4mg of  Tolterodine  Tartrate  were  transferred  into  each  of  the  six
dissolution jars and the apparatus was run. At the end of the 1st, 2nd, 4th and 8th hours 10ml of the
sample solution were withdrawn from each dissolution jars and same volume was replaced using
the  prepared  medium.  Temperature  was  maintained  at  37±0.5ºC.  The  solution  was  filtered
through 0.45µ nylon filter.
Procedure:
100µl of dissolution media, six replicate injections of standard solution and single injection of
sample solutions  were  separately injected  into  the  chromatograph.  The  chromatograms were
recorded and peak responses were measured.
System Suitability:
The peak responses were recorded for standard preparation and sample preparation. The relative
standard deviation for six replicate standard solution injections should not be more than 2%. The
tailing factor for Tolterodine Tartrate peak should not be more than 2.0. Theoretical plates for
Tolterodine Tartrate peak should not be less than 2000.
Calculation:
% labeled amount of Tolterodine Tartrate dissolved
AT     WS         1         900                  P
-------x--------x--------x--------x------------------- x 100
AS      50      100       WT          % Label Claim
Where,
        AT = Absorbance of Tolterodine Tartrate sample solution
        AS = Absorbance of Tolterodine Tartrate standard solution
        WS = Weight of Tolterodine Tartrate in working standard(mg)
        WT =  Weight of Tolterodine Tartrate pellets taken (mg)
        P = Potency of Tolterodine Tartrate working standard used
5.4.9. Dissolution profile comparision using Similarity and Dissimilarity Factors.
                    f1=Dissimilarity factor
                    f2=Similarity factor
A dissolution  profile  characterizes  the  product  more  precisely  than  a  single  point
dissolution  test.  It  helps  to  assure  similarity  in  product  performance  and  signals
bioequivalence. The factor f1 is proportional to the average indifference between two
profiles, where as factor f2 inversely proportional to the average squared indifference
between two profiles. The factor f2 measures the closeness between two profiles. FDA
has set a public standard of f2 value between 50-100 to indicate similarity between two
profiles.
f1= ΣD (1/ Σt) 100
f2 = 50 x ln{1/1+Σ (Rt-Tt)2}
Procedure: The mean dissolution values of the two profiles (test and innovator) are taken which
should be made under same test conditions and same time points. The time points are taken as
1,4,7 hours. The following mathematical approach is made to compare the dissolution profiles of
Tolterodine Tartrate pellets using two factors f1 and f2. 
5.4.10. Stability Studies
Stability studies are an integral part of the drug development program and are one of the most
important areas in the registration of pharmaceutical products. The purpose of stability  testing is
to provide evidence on how the quality of a drug substance or drug product varies with time
under the influence of a variety of environmental factors such as temperature, humidity, light and
enables recommended storage conditions, re-test periods and shelf half- lives to be established.
Stability  assessment  starts  with  studies  on  the  substance  to  determine  degradation  products,
degradation pathway. In these type of studies the pellets are stored in suitable containers and
stability study is  conducted  as  per  ICH guidelines.  The  product  is  analyzed  at  intervals  for
various  parameters  which  may  include  assay  of  active  ingredient,  measurement  of  known
degradation products, hardness, disintegration time, dissolution time, appearance, etc., Stability
studies have been conducted at following conditions.27
Storage conditions:40 ºC ± 2 ºC /75%RH ± 5%RH, 25 ºC ± 2 ºC /60% RH ± 5% RH
Packs: Capsules containing pellets have been packed into blister packages.
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6.1. Analytical Method Development:
6.1.1. Scanning of λ max:
For the selection of analytical wavelength, 10 µg/ml solution of Tolterodine was prepared by
appropriate dilution of standard stock solution(1mg/ml) and scanned in the spectrum mode from
200 nm to 400 nm.From the spectra of drug λmax of Tolterodine tartrate, 284.5 nm was selected
for the analysis.
6.1.2. Preparation of standard curve:
The maximum absorption was observed at 284.5nm. 1mg/ml (1000µg/ml) solution was prepared
by dissolving 100mg in 100 ml of Methanol. From the secondary stock (100 µg/ml) 0.5, 1.0, 1.5,
2.0, and 2.5 ml, was taken separately and made up to 10 ml with Methanol to produce 5, 10, 15,
20  and  25  µg/mL  respectively.  The  absorbance  was  measured  at  284.5nm  using  a  UV
spectrophotometer.
Table 12: Standard values of Tolterodine Tartrate
Concentration (µg/ml) Absorbance
0 0
5 0.145
10 0.275
15 0.405
20 0.535
25 0.665
0 5 10 15 20 25 30
0
0.1
0.2
0.3
0.4
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0.7
f(x) = 0.03x + 0.01
R² = 1
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Fig:12 Standard Graph of Tolterodine
6.2. Pre-Formulation Studies:                                                        
Table 13: Characterization of Tolterodine tartarate
S.No Test Specification Result
1. Description A white or off –white powder A white or off-white
powder
2. Solubility Very soluble in water, soluble in
methanol, slightly soluble in
ethanol and practically insoluble
in toluene
 
Complies
3. Water content
(by Karl-Fisher)
Not more than 0.8%w/w Complies
4. LOD By I.R moisture analyser,105C ≤1.0 % w/w
5. Assay on anhydrous
basis(potentiometric)
<98% and not more than 102% 99.8%w/v
6. Part size analysis 0.420mm 0.420mm
7. Melting point 205°C 205°C
 Table 14 : Result of preformulation study of  Tolterodine tartarate
Parameter Result
Angle of repose (o) 33
Bulk density (g/cm3) 0.3
True density(g/cm3) 0.45
Carr’s compressibility index (%) 33.333
Hausner’s ratio 1.5
Solubility: 
The solubility of the drug was determined by the equilibrium solubility method, which employs a
saturated  solution of  the  material,  obtained by stirring an  excess  of  material  in  the  solvent,
ranging from polar to non-polar for a prolonged period until  equilibrium is achieved. It  was
inferred  that  11mg of  Tolterodine  Tartrate  was  soluble  in  1ml  of  Water,1mg of  Tolterodine
Tartrate was soluble in 1ml of Ethanol and Methanol,5.8mg of Tolterodine Tartrate was soluble
in 1ml of Oleic acid, 6.69mg of Tolterodine Tartrate was soluble in 1ml of Ethyl acetate.
6.3.1. Physical Compatibility:
Compatibility studies were carried out to study the possible interactions between Tolterodine
Tartrate and the polymers used for coating in the formulation. The method employed for the
analysis was the KBr pellet method. The mixtures were exposed to different storage conditions
and the samples were collected at regular intervals and were tested with respect to their physical
and chemical aspects.
                      Table 15.Physical Compatibility Results
Material
Sample Status After
1 month, kept at
Accelerated
40oC±2oC/75%
RH±5% RH
Sample Status
After 1  month,
kept at 25ºC ±
2ºC /60%RH ± 5%
RH
Tolterodine Tartrate No Change No Change
Tolterodine Tartrate + HPMC No Change No Change
Tolterodine Tartrate + Ethyl
Cellulose
No Change No Change
6.4. FOURIER TRANSFORM INFRARED SPECTROSCOPY
The I.R spectrum of drug alone and with the excipients was observed
 Figure 13 : I.R Spectrum of Drug
                                    Figure 14: I.R Spectrum of Drug + HPMC
       
                         Figure 15: I.R spectrum of Drug +Ethyl cellulose 
Table 16: Comparision of the characteristic I.R peaks corresponding to the functional 
groups in Tolterodine tartarate with physical mixture of different excipients
Correspondig 
functional 
groups
Literature 
value
(wave 
numbercm-1)
Characteristc
peaks of drug
alone 
(wave 
number cm-1)
Drug +HPMC
( wave 
number cm-1)
Drug 
+EC
( wave 
number
cm-1)
Tertiary amine 
group N-H 
stretching
3500-3100 3415.54 3416.32 3417.75
Aliphatic 
alkane
C-H stretching
2960-2850 2944.95 2924.22 2925.70
Phenolic O-H 
stretching
1300-1200 1212.39 1009.43 1124.27
Aromatic C=C 
group 
stretching
1600-1450 1598.77 1619 1620.16
6.5. Evaluation of Pellets:
6.5.1. Sieve Analysis:
All the Tolterodine Tartrate formulations were tested for particle size by sieve analysis using
mechanical sieve shaker. Not more than 90% of pellets pass through 18 number mesh and not
less than 90% pellets are retained on 22 number mesh.
6.5.2. Percentage Moisture content: 
30ml of methanol is taken in a clean, dried Karl  Fischer  titration flask and titrated with KF
reagent until the end point to neutralize the free water. Tolterodine Tartrate pellets are powdered
finely. Accurately weighed quantity of 0.5gm of sample is transferred to the titration flask and
dissolved by stirring and titrate with KF reagent to the end point and percentage water content is
calculated
Table 17: Percentage Moisture content
S. No Formulation % Moisture
Content
1 Trial I 1.72
2 Trial II 1.95
3 Trial III 1.81
4 Trial IV 1.88
5 Trial V 1.92
6 Trial VI 1.89
7 Trial VII 1.87
8 Trial VIII 1.85
6.6. Evaluation of Capsules Containing Pellets:
6.6.1. Weight variation: 
            20 intact capsules are selected randomly and weighed and average weight is calculated. 
Individual weight of each capsule is determined. According to USP, none of the individual 
capsule weight should be less than 90% and more than 110% of the average weight.
Table 18: Weight Variation
SNo Formulation Average Weight (mg)
1 Trial I 333.5 ± 3.6
2 Trial II 334.2 ± 5.8
3 Trial III 333.7 ± 4.5
4 Trial IV 334.5 ± 3.5
5 Trial V 333.6 ± 3.2
6 Trial VI 333.3 ± 4.5
7 Trial VII 334.1 ± 4.6
8 Trial VIII 333.6 ± 3.7
6.6.2. Content Uniformity:
Capsules containing Tolterodine Tartrate formulations have shown the drug content uniformity in
the range of 98.3%-100.5%. According to USP, 30 intact capsules are selected, of which 10 are
assayed. 9 of 10 capsules should be within the potency range of 85%-115%. The potency of
10thcapsule should not exceed the range of 75-125% 
Table 19: Content Uniformity
SNo Formulation %Drug Content
1 Trial I 98.5 ± 0.2
2 Trial II 99.7 ± 0.3
3 Trial III 100.1 ± 0.2
4 Trial IV 99.5 ± 0.4
5 Trial V 98.3 ± 0.3
6 Trial VI 99.7 ± 0.4
7 Trial VII 99.9 ± 0.2
8 Trial VIII 100.1± 0.3
6.6.3. Assay by HPLC
100µl, six replicate injections of standard solution and single injection of sample solution were
injected. The chromatograms are recorded and the peak response was measured. The assay (in
%) was calculated by using following formula.
                                  AT     WS     2       250      50       P           100
%Drug Content = ------x-------x-----x--------x-----x------x-------------------x100
                                  AS     50     100      WT        5     100     Label claim
Where,
AT  = Peak area of Tolterodine Tartrate in sample solution
AS  = Average peak area of Tolterodine Tartrate in standard solution
WS  =Amount of Tolterodine Tartrate taken in working standard (mg)
WT  =Amount of sample (mg)
P    = Potency of Tolterodine Tartrate working standard used.
Capsules containing Tolterodine Tartrate formulations have shown the assay (in %) in the range
of 92.7%-100.1%.
Table 20: Percentage Drug Content
S No Formulation %Drug Content
1 Trial I 93.5 ± 0.2
2 Trial II 92.7 ± 0.3
3 Trial III 95.1 ± 0.2
4 Trial IV 94.5 ± 0.4
5 Trial V 97.3 ± 0.3
6 Trial VI 95.7 ± 0.4
7 Trial VII 98.2 ± 0.2
8 Trial VIII 100.1± 0.3
Chromatogram
Fig.16: Assay Of Blank Solution
    Chromatogram
Detector Ach 1 215nm
Peak # Name Ret. Time Area Area% Theoretical 
plate #
Tailing 
factor
1 Tolterodine 9.22 2098348 100.00 3950 1.4
Total 2098348 100.00
Fig. 17: Assay Of Standard Solution
    Chromatogram
Detector Ach 1 215nm
Peak # Name Ret. Time Area Area% Theoretical 
plate #
Tailing 
factor
1 Tolterodine 9.25 2309750 100.00 3440 1.4
Total 2309750 100.00
Fig. 18: Assay Of Sample Solution
6.6.4. Dissolution by HPLC:
100µl of dissolution media, six replicate injections of standard solution and single injection of
sample solutions  were  separately injected  into  the  chromatograph.  The  chromatograms were
recorded and peak responses were measured.
% labeled amount of Tolterodine Tartrate dissolved
AT     WS         1         900                  P
-------x--------x--------x--------x----------------------- x 100
AS      50      100       WT          % Label Claim
Where,
        AT = Absorbance of Tolterodine Tartrate sample solution
        AS = Absorbance of Tolterodine Tartrate standard solution
        WS = Weight of Tolterodine Tartrate in working standard(mg)
        WT =  Weight of Tolterodine Tartrate pellets taken (mg)
        P = Potency of Tolterodine Tartrate working standard used
Table 21: Innovator Drug Release Profile
SNo Time(hrs) %Drug release
0 0
1 1 23.30
2 2 46.7
3 4 71.5
4 8                      93.5
Table 22: Comparative Dissolution Data
S.
No
Time
(hrs)
%Drug Release
Innovator
Trial
I
Trial
II
Trial
III
Trial
IV
Trial
V
Trial
VI
Trial
VII
Trial
VIII
0 0 0 0 0 0 0 0 0 0 0
1 1 23.30 10.3 11.3 12.7 17.5 18.2 19.7 29.5 25.50
2 2 46.7 21.8 22.4 23.8 25.1 30.4 33.8 42.1 49.10
3 4 71.5 38.1 38.9 41.3 59.5 60.8 64.3 68.5 74.50
4 8 93.5 56.7 59.7 68.3 78.4 81.6 84.3 89.4 95.60
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Fig: 19. Comparative in vitro drug release profile of Trials I-VII1
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Figure 20.Comparative in vitro drug release profile of Trial VIII (optimized trial) with
Innovator
Eight formulations of sustained release pellets were prepared by incorporating Ethyl cellulose
and PVPK-30 as a pore former. From the initial 3 trials with the varying concentration of Ethyl
cellulose the dissolution results suggested that when the concentration was high the drug release
was retarded from initial to the end point and at low concentration the drug release was higher
than the reference product at the initial hours and incomplete release at the end of the dissolution.
By observing the incomplete release from the coated pellets even at low concentration of Ethyl
cellulose a barrier coating polymer is incorporated from trial 4 and varying the concentration of
Ethyl cellulose was studied. From all the above studies it is concluded that the batch with 4.3%
of HPMC as barrier coat and 3.2% Ethyl Cellulose with 1.6% of PVPK-30 found to be the best
of all the trials matching the innovator product. For all the batches the prepared pellets were
filled in to Size 3 capsules and analyzed.
6.6.5.DRUG RELEASE KINETICS:   
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Figure 21: First order graph kinetics of Trials I-IV.
0 1 2 3 4 5 6 7 8 9
0
0.5
1
1.5
2
2.5
f5
Linear (f5)
f6
Linear (f6)
f7
Linear (f7)
f8
Linear (f8)
TIME(hrs)
L
o
g
  
 c
u
m
u
la
ti
v
e
%
 D
ru
g
 u
n
re
le
a
se
d
      
Figure 22: First order graph kinetics of Trials V-VIII. 
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Figure 23 :  First order graph of innovator & optimized trail (f8)
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Figure 24 : Higuchi plot  of  innovator product & optimized trial (f8)
The kinetic analysis of the drug release data reveal that the pattern of drug delivery follows first
order and matrix diffusion as shown by the straight lines  (FIG 21-24).
6.6.6. F1& F2 Values for formulations:
A dissolution  profile  characterizes  the  product  more  precisely  than  a  single  point
dissolution  test.  It  helps  to  assure  similarity  in  product  performance  and  signals
bioequivalence. The factor f1 is proportional to the average indifference between two
profiles, where as factor f2 inversely proportional to the average squared indifference
between two profiles
f1= ΣD (1/ Σt) 100
f2 = 50 x ln{1/1+Σ (Rt-Tt)2}
The mean dissolution values of the two profiles (test and innovator) are taken which were made
under same test conditions and same time points. The time points were taken as 1, 4, 7 hours.
The above mathematical approach is made to compare the dissolution profiles of Tolterodine
Tartrate  pellets  using two factors  f1  and f2.  The Similarity and  Dissimilarity values  for  the
optimized Trial VIII were found to be 5.49and 79.36 respectively.
Table 23: Similarity and Dissimilarity Values for formulations
6.6.7. Stability Results:
Table 24: Stability Results for selected formulation
Value Trials
Trial
I
Trial
II
Trial
III
Trial
IV
Trial
V
Trial
VI
Trial
VII
Trial
VIII
F1 17.17 9.39 9.39 5.76 22.77 22.87 11.45 5.49
F2 45.19 58.09 57.98 68.21 40.11 40.54 54.91 79.36
SNo Test
Storage Condition 40ºC ±
2ºC /75%RH ± 5%RH
Storage Condition 25ºc ±
2ºC /60%RH  ± 5% RH
Initial 90 days Initial 90 days
1
Physical
Appearance
White White White White
2
% Moisture
Content
1.25 1.26 1.25 1.25
3
% Drug
Content
100.1 99.9 100.1 100
4
% Drug
Release
93 92.9 93 92.9
                  It was concluded that stability studies of the optimized Trial VIII was carried out
using the samples at different temperatures 400C ± 20C, 75% ± 5%RH and 250C ± 20C, 60% ±
5%RH  for a period of three months, the capsules are observed and there is no significant change
in the release characteristics and physicochemical properties of the capsules.
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Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. It  is a tertiary
amine with relatively low lipophilicity. Tolterodine has a pronounced effect on bladder function.
The  main  effects  of  Tolterodine  are  an  increase  in  residual  urine,  reflecting  an  incomplete
emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic
action on the lower urinary tract.
The main aim and objective was to develop Sustained release capsules of Tolterodine Tartrate in
order to meet the required bioavailability and to study the in-vitro release pattern of the test
formulation against the Innovator product.
In the current study Tolterodine Sustained release pellets were prepared by Layering of the drug
on core pellets by fluid bed processor (Wurster) and coating of the drug layered pellets with the
sustained release polymers  with the same process  of Fluid bed processor  (Wurster).  For  the
layering of the drug on core pellets the drug solution was prepared by using HPMC as a binder
with the suspension layering technique. HPMC at 6% concentration was used constantly and at
6% concentration the Drug layered pellets is found to be satisfactory without any doublets or
triplets. Further the pellets assay results suggested that there is no loss of drug. Hence throughout
the process the concentration of HPMC for drug layering maintained constantly at 6% level. 
Eight formulations of sustained release pellets were prepared by incorporating Ethyl cellulose
and PVPK-30 as a pore former. From the initial 3 trials with the varying concentration of Ethyl
cellulose the dissolution results suggested that when the concentration was high the drug release
was retarded from initial to the end point and at low concentration the drug release was higher
than the reference product at the initial hours and incomplete release at the end of the dissolution.
By observing the incomplete release from the coated pellets even at low concentration of Ethyl
cellulose a barrier coating polymer is incorporated from trial 4 and varying the concentration of
Ethyl cellulose was studied. From all the above studies it is concluded that the batch with 4.3%
of HPMC as barrier coat and 3.2% Ethyl Cellulose with 1.6% of PVPK-30 found to be the best
of all the trials matching the innovator product. For all the batches the prepared pellets were
filled in to Size 3 capsules and analyzed.
The kinetic analysis of the drug release data reveal that the pattern of drug delivery follows first
order and matrix diffusion as shown by the straight lines.
The identified formulation f8 which was matching to the reference product on the basis of f1, f2
values  was manufactured again with the same process parameters to confirm the reproducibility.
The  result  of  the  reproducibility batch  is  found to  be superimposable to  the final  identified
formulation. 
Stability study was carried out for 3 months at 25°C±2°C; 60%±5% RH: and 40°C±2°C; 75%
±5% RH, according to ICH guidelines for the final formulation and the results are found to be
stable.
The optimized formula shall be utilized for the formulation development and other studies like
bio-equivalence study, for successful launching of the product.
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